{"id":1448,"date":"2025-02-19T13:37:42","date_gmt":"2025-02-19T19:37:42","guid":{"rendered":"https:\/\/asipagac.com\/?page_id=1448"},"modified":"2025-03-19T14:04:49","modified_gmt":"2025-03-19T20:04:49","slug":"sobre-la-condicion","status":"publish","type":"page","link":"https:\/\/asipagac.com\/en\/sobre-la-condicion\/","title":{"rendered":"Sobre la condicion"},"content":{"rendered":"<div data-elementor-type=\"wp-page\" data-elementor-id=\"1448\" class=\"elementor elementor-1448\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e6f821b e-con-full e-flex e-con e-parent\" data-id=\"e6f821b\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4ac82dd el-align-center elementor-widget elementor-widget-dl_page_header\" data-id=\"4ac82dd\" data-element_type=\"widget\" data-widget_type=\"dl_page_header.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"el-page-header\">\r\n\t\t\t<div class=\"overlay\"><\/div>\t\t\t<div class=\"container-fluid\">\r\n\t\t\t\t<div class=\"el-ph-content\">\r\n\t\t\t\t\t<h2 >About the disease<\/h2>\t\t\t\t\t<p >The Glutaric Acidemia is a rare metabolic disorder that affects the way in which <br>\nthe body processes certain proteins and fats. It is a hereditary condition, <br>\nmeaning it is passed down from parents to children through genes. There are\ntwo types  <br>of Glutaric Acidemia: type I and Type II, each with\nspecific characteristics and effects.<\/p>\t\t\t\t\t\t\t\t\t\t<ol class=\"breadcrumb-wrap\">\r\n\t\t\t\t\t\t<li><a href=\"https:\/\/asipagac.com\/en\/\">\r\n\t\t\t\t\t\t<i class=\"ti-home\"><\/i>Home\t\t\t\t\t\t<\/a><\/li>\r\n\t\t\t\t\t\t<li class=\"active\">\r\n\t\t\t\t\t\tAbout the disease\t\t\t\t\t\t<\/li>\r\n\t\t\t\t\t<\/ol>\r\n\t\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-bb57478 elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"bb57478\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-be82f07\" data-id=\"be82f07\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-ced54d9 elementor-invisible elementor-widget elementor-widget-sc-heading\" data-id=\"ced54d9\" data-element_type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInUp&quot;}\" data-widget_type=\"sc-heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div id=\"wt-at-ced54d9\" class=\"headng-wrap left\">\r\n\t\t\t<div class=\"section-heading\">\r\n\t\t\t\t\t\t\t<h4\r\n\t\t\t\t \t\t\t\t>GA Type 1<\/h4>\r\n\t\t\t\t\t\t\t\t\t\t\t\t<h2\r\n\t\t\t\t \t\t\t\t>Glutaric  Acidemia type 1 <br> (GAT AGT)<\/h2>\r\n\t\t\t\t\t\t\t\t\t\t\t\t<p\r\n\t\t\t\t \t\t\t\t>The Glutaric  Acidemia Type 1 is an inherited metabolic condition that hinders the processing of  certain amino acids. It is manifested by too much glutaric acid in the\nurine and\/or blood<\/p>\r\n\t\t\t\t\t\t\t<\/div>\r\n\t\t<\/div>\r\n\r\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-d008f16\" data-id=\"d008f16\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5541965 tipo-condicion-imagen elementor-widget elementor-widget-sc_video_box\" data-id=\"5541965\" data-element_type=\"widget\" data-widget_type=\"sc_video_box.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t        <div class=\"dl-video-box-wrap\">\r\n            <img fetchpriority=\"high\" decoding=\"async\" width=\"825\" height=\"550\" src=\"https:\/\/asipagac.com\/wp-content\/uploads\/2025\/03\/ga-tipo-1-video-1024x683.jpg\" class=\"attachment-large size-large wp-image-1848\" alt=\"\" srcset=\"https:\/\/asipagac.com\/wp-content\/uploads\/2025\/03\/ga-tipo-1-video-1024x683.jpg 1024w, https:\/\/asipagac.com\/wp-content\/uploads\/2025\/03\/ga-tipo-1-video-300x200.jpg 300w, https:\/\/asipagac.com\/wp-content\/uploads\/2025\/03\/ga-tipo-1-video-768x512.jpg 768w, https:\/\/asipagac.com\/wp-content\/uploads\/2025\/03\/ga-tipo-1-video.jpg 1500w\" sizes=\"(max-width: 825px) 100vw, 825px\" \/>\t\t\t            <div class=\"dl-video-box-overlay\">\r\n\t\t\t\t\t\t\t\t                <div class=\"dl-video-box-icon\">\r\n                    <a href=\"https:\/\/www.youtube.com\/watch?v=jyscRA5CY68\" class=\"veno-lightbox\" data-overlay=\"\" data-autoplay=\"true\" data-vbtype=\"video\">\r\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"dl-vb-2\">\r\n\t                            <i class=\"fa fa-play\"><\/i>\r\n\t                            <div class=\"ripple\"><\/div>\r\n\t                        <\/div>\r\n\t\t\t\t\t\t                    <\/a>\r\n                <\/div>\r\n\t\t\t\t            <\/div>\r\n\t\t\t        <\/div>\r\n        \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t<div class=\"elementor-element elementor-element-9e9125e e-flex e-con-boxed e-con e-parent\" data-id=\"9e9125e\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7d849f75 elementor-widget elementor-widget-n-accordion\" data-id=\"7d849f75\" data-element_type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;all_collapsed&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-2100\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-2100\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Our professionals explain  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2100\" class=\"elementor-element elementor-element-39b463ce e-con-full e-flex e-con e-child\" data-id=\"39b463ce\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-469587d9 elementor-widget elementor-widget-text-editor\" data-id=\"469587d9\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Glutaric Acidemia type 1 (GAT AGT) is an uncommon condition, which comes within the congenital errors of the metabolism of the organic acids (OOA) .\u00a0<\/p><p><span style=\"vertical-align: inherit;\">It is considered a neurometabolic disease or organic brain aciduria , a metabolic disease whose target organ is the brain, with symptoms primarily neurological.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-2101\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"2\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-2101\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Definition <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2101\" class=\"elementor-element elementor-element-7d95e0b4 e-con-full e-flex e-con e-child\" data-id=\"7d95e0b4\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6bacd625 elementor-widget elementor-widget-text-editor\" data-id=\"6bacd625\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>The Glutaric  Acidemia type 1 is expressed primarily in the central nervous system, with neurological symptoms that usually include movement disorders, developmental delay, psychomotor, and, in severe cases, irreversible brain damage. The symptoms can appear in childhood and worsen if not diagnosed and treated on time. Although some patients may not show symptoms in the first few years of life, the disease is often triggered during episodes of febrile illness, or metabolic stress.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-2102\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"3\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-2102\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Cause <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2102\" class=\"elementor-element elementor-element-60a716f3 e-con-full e-flex e-con e-child\" data-id=\"60a716f3\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5524fd2d elementor-widget elementor-widget-text-editor\" data-id=\"5524fd2d\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">The cause of the GA-1 mutations are in the <\/span><a href=\"http:\/\/ghr.nlm.nih.gov\/gene\/GCDH\"><span style=\"font-weight: 400;\">gene GCDH<\/span><\/a><span style=\"font-weight: 400;\">located on 19p13.2, which gives the instructions for a protein of the mitochondrial matrix-dependent flavin-adenine-dinucle\u00f3tidopara to produce the enzyme glutaril-CoA dehydrogenase located in the <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3675899\/\"><span style=\"font-weight: 400;\">mitochondria<\/span><\/a><span style=\"font-weight: 400;\">, liver, kidney, <\/span><a href=\"https:\/\/www.genome.gov\/glossarys\/index.cfm?id=63\"><span style=\"font-weight: 400;\">fibroblasts<\/span><\/a><span style=\"font-weight: 400;\"> and <\/span><a href=\"https:\/\/www.cancer.gov\/espanol\/publicaciones\/diccionario\/def\/leucocito\"><span style=\"font-weight: 400;\">leukocytes<\/span><\/a><span style=\"font-weight: 400;\">; which is responsible for the dehydrogenation of the glutaril-CoA and the decarboxylation of glutaconil-CoA to crotonil-CoA, is involved in the catabolic pathways of the<\/span><a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/L-lysine#section=Top\"><span style=\"font-weight: 400;\"> L-lysine<\/span><\/a><span style=\"font-weight: 400;\">, L-hydroxylysine and <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2908021\/pdf\/ijtr-2-2009-045.pdf\"><span style=\"font-weight: 400;\">L-tryptophan<\/span><\/a><span style=\"font-weight: 400;\">; found in all foods that contain protein.<\/span><\/p><p><span style=\"font-weight: 400;\">The most prevalent mutation in Spain are: R402W (enzyme activity almost zero, high concentration of metabolites), A293T (enzyme activity almost zero, high concentration of metabolites), V400M (residual enzyme activity, excretion mild metabolites), R227P (residual enzyme activity, excretion minor metabolite).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-2103\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"4\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-2103\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> What happens  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2103\" class=\"elementor-element elementor-element-464de0fe e-con-full e-flex e-con e-child\" data-id=\"464de0fe\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3d90b00f elementor-widget elementor-widget-text-editor\" data-id=\"3d90b00f\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">In people with GA-1 <\/span><a href=\"http:\/\/ghr.nlm.nih.gov\/gene\/GCDH\"><span style=\"font-weight: 400;\">enzyme intramitochondrial glutaril-CoA dehydrogenase deficiency<\/span><\/a><span style=\"font-weight: 400;\">, does not work well or does not occur at all; this causes the incomplete degradation of lysine, tryptophan and hidrolysine, which gives rise to elevated levels of <\/span><span style=\"font-weight: 400;\">glutaric acid, acid-3-hidroxiglut\u00e1rico, acid glutac\u00f3nico and glutarilcarnitina C5D5<\/span><span style=\"font-weight: 400;\">, which cannot be removed and accumulate in the blood and urine. These may affect the health, growth, development and learning.<\/span><\/p><p><span style=\"font-weight: 400;\">A higher intake of lysine according to individual tolerance, or due to the catabolism during acute episodes of illness, fever, surgical intervention or reaction vaccine increase the levels of lysine in the brain and in consequence of the metabolites AG, 3-OH-ga and Glutaril-CoA.<\/span><\/p><p><span style=\"font-weight: 400;\">The blood-brain barrier \"catches\" these metabolites, which accumulate and negatively affect the brain's energy metabolism.<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"2\"><i><span style=\"font-weight: 400;\">Glutaril-CoA<\/span><\/i><i><span style=\"font-weight: 400;\"> inhibits the complex 2-oxoglutarate dehydrogenase<\/span><\/i><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><i><span style=\"font-weight: 400;\">AG<\/span><\/i><i><span style=\"font-weight: 400;\"> hinders the transport of dicarboxylic acids between astrocytes and neurons<\/span><\/i><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><i><span style=\"font-weight: 400;\">Ga and 3-OH-AG<\/span><\/i><i><span style=\"font-weight: 400;\"> indirectly modulate  the  neurotransmission of GABA and glutamate, causing an imbalance of neurotransmission.<\/span><\/i><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><i><span style=\"font-weight: 400;\">3-OH-AG<\/span><\/i><i><span style=\"font-weight: 400;\"> induces cellular damage, cytotoxic pathway receptors N-methyl-D-aspartate (NMDA) *2<\/span><\/i><\/li><\/ul><p><i><span style=\"font-weight: 400;\">The accumulation at brain level of these metabolites produces neurological damage.\u00a0<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">Often been noted an increase in the excretion of dicarboxylic acids, 2-oxoglutarate, and succinate, indicative of mitochondrial dysfunction. *2<\/span><\/i><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\">\u00a0<\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">The<\/span><a href=\"https:\/\/es.wikipedia.org\/wiki\/Lisina\"><span style=\"font-weight: 400;\"> L-lysine<\/span><\/a><span style=\"font-weight: 400;\"> is a necessary element for the construction of all the proteins of the organism it plays an important role in the absorption of calcium; in the construction of muscle proteins; in the recovery of surgical interventions or sports injuries, and in the production of hormones, enzymes and antibodies.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">The <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2908021\/pdf\/ijtr-2-2009-045.pdf\"><span style=\"font-weight: 400;\">L-tryptophan<\/span><\/a> <span style=\"font-weight: 400;\">is necessary for the production of serotonin in the nervous system and its lack can cause neurological deficit. So the diet should be low in tryptophan, do not remove it completely.<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">Normally, people with GA-1 are apparently healthy, but the accumulation of the toxic attached to different processes (situations that cause metabolic stress), can cause serious episodes called <\/span><span style=\"font-weight: 400;\">metabolic crisis<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\">\u00a0<\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Disease or infection. Vomiting and diarrhea are common and should be monitored closely.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Fever<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Prolonged fasting<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Vaccine<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Surgery<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">The body is in balance (homeostasis), but during these processes, the balance is broken, it increases the degradation of proteins, and releases the amino acids (including <\/span><a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/L-lysine#section=Top\"><span style=\"font-weight: 400;\">lysine<\/span><\/a><span style=\"font-weight: 400;\"> and<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2908021\/pdf\/ijtr-2-2009-045.pdf\"><span style=\"font-weight: 400;\"> tryptophan<\/span><\/a><span style=\"font-weight: 400;\">)  having the disease patients do not have the enzyme to degrade them, and they accumulate the intermediate products of this reaction, acting as a <\/span><span style=\"font-weight: 400;\">toxic<\/span><span style=\"font-weight: 400;\"> that can lead to clinical deterioration or metabolic crisis and damage the brain.<\/span><\/p><p><span style=\"font-weight: 400;\">At a  neuropathological level the encephalopathic crisis during the development of the brain (usually in the first 6 years of life) causes a bilateral striatal  injury (caudate and putamen); or develops insidiously without a clinically apparent crisis. The cause of the neurological dysfunction has not been well understood so far.<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Acute phase: first 24 hours, with cytotoxic edema within the basal ganglia, poor cerebral perfusion, and rapid transit of the blood through the gray matter.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Subacute stage: 4 to 5 days after the onset of clinical symptoms, decreased perfusion striatal and the uptake of glucose , and vasogenic edema.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Chronic stage: the atrophy of striatal.<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">The acute encephalopathic crisis  causes  permanent severe neurological disability, particularly a movement disorder. However, with an early aggressive treatment the neurological complications can be prevented<\/span><\/p><p><span style=\"font-weight: 400;\">Patients under 6 years of age are at higher risk of neurological damage, so that the treatment of children should be very careful. The treatment aims to minimize the accumulation of toxic metabolites by preventing the degradation of proteins and promote its excretion with the use of carnitine.<\/span><\/p><p><span style=\"font-weight: 400;\">\u00a0<\/span><\/p><p><i><span style=\"font-weight: 400;\">The variants of acute onset and insidious onset is manifested during the first six years of life, whereas individuals with late-onset often manifests itself during adolescence or early adulthood*1.<\/span><\/i><\/p><p><span style=\"font-weight: 400;\">The acute encephalopathic crisis  causes  permanent severe neurological disability, particularly a movement disorder. However, with an early aggressive treatment the neurological complications can be prevented<\/span><\/p><p><span style=\"font-weight: 400;\">Patients under 6 years of age are at higher risk of neurological damage, so that the treatment of children should be very careful. The treatment aims to minimize the accumulation of toxic metabolites by preventing the degradation of proteins and promote its excretion with the use of carnitine.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-2104\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"5\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-2104\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Prevalence  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2104\" class=\"elementor-element elementor-element-192e5220 e-con-full e-flex e-con e-child\" data-id=\"192e5220\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3f54b190 elementor-widget elementor-widget-text-editor\" data-id=\"3f54b190\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><b><i>Incidence in the world, estimated 1:110.000. *1 and *2<\/i><\/b><\/p><p><span style=\"font-weight: 400;\">Incidence in Spain between 1:40000-50000 in communities such as Galicia and Madrid.<\/span><\/p><p><span style=\"font-weight: 400;\">There are 5 known populations with a higher frequency of carriers (up to 1:10) and incidence (up to 1:250)<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The Amish community in Lancaster county, Pennsylvania, united States<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The First Nations Oji-Cree in Manitoba and western Ontario, Canada<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Irish nomads in Ireland and the United Kingdom<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The Lumbee in North Carolina, United States<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The Xhosa, and other subgroups of the population of South Africa<\/span><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-2105\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"6\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-2105\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Prognosis  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2105\" class=\"elementor-element elementor-element-2b336d53 e-con-full e-flex e-con e-child\" data-id=\"2b336d53\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-10d0795c elementor-widget elementor-widget-text-editor\" data-id=\"10d0795c\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><b>The prognosis depends on early diagnosis, management and appropriate treatment, both the standard treatment as well as emergency treatment.<\/b><span style=\"font-weight: 400;\">.<\/span><b> It is now considered a treatable disease. In general, if treatment begins before you have symptoms, children with GA1 will grow and develop normally.<\/b><\/p><p><span style=\"font-weight: 400;\">If not treated immediately and properly, it can cause neurological damage, which will cause a higher risk of medical problems. 80-90% of patients who do not receive treatment, will develop an encephalopathic crisis during the period of greatest vulnerability, between 3-36 months; due to an illness, fever, surgical intervention or reaction to the vaccination. The damage mainly affects the control of voluntary muscle movement .<\/span><\/p><p><span style=\"font-weight: 400;\">Some people only look mildly affected, while others have severe problems. In most cases, the signs and symptoms first appear in infancy or early childhood, but in a small number of affected individuals, the disorder becomes apparent for the first time in adolescence or adulthood, or remain asymptomatic or with minimal neurological disorders.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-2106\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"7\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-2106\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Classification  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2106\" class=\"elementor-element elementor-element-7a57c3ae e-con-full e-flex e-con e-child\" data-id=\"7a57c3ae\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-319ad647 elementor-widget elementor-widget-text-editor\" data-id=\"319ad647\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Classification according to the clinical onset:<\/p><ul><li aria-level=\"1\">Acute onset: <i>acute onset,<\/i> the most frequent; neurological and <i>bilateral striatal injury<\/i> after encephalopathic crisis with psychomotor regression (regression, loss of developmental milestones acquired) and severe movement disorder. 80-90% of untreated children in the first six years of life.<\/li><\/ul><ul><li aria-level=\"2\">Hypotonia of the neck and trunk<\/li><\/ul><ul><li aria-level=\"2\">Stiffness of limbs<\/li><\/ul><ul><li aria-level=\"2\">Athetosis of the hands and feet (involuntary movements)<\/li><\/ul><ul><li aria-level=\"2\">Loss of skills (sitting, standing, sucking, swallow...)<\/li><\/ul><ul><li aria-level=\"1\">Insidious onset: <i>insidious onset,<\/i> develop neurological and <i>striatal damage<\/i> without encephalopathic crisis ,less serious (usually in individuals who do not follow dietary recommendations). Corresponds with the 10-20% of those affected with symptoms. In magnetic resonance imaging patients have less extensive lesions usually in the <i>dorsolateral putamen area<\/i>, with a lag phase without symptoms after their appearance<\/li><\/ul><ul><li aria-level=\"1\">Late start: <i>late on set<\/i>, nonspecific mild symptoms after six years, without damage of the nucleus striatum. Recent studies have identified changes in the resonance in the high excretory, possibly related to a higher accumulation in the brain and chronic neurotoxicity. In the magnetic resonance imaging we can observe <i>lesions in the periventricular white matter <\/i>*1 and *2<\/li><\/ul><ul><li aria-level=\"2\">Headache<\/li><\/ul><ul><li aria-level=\"2\">Ataxia (control poor muscle that causes awkward movements volunteers)<\/li><\/ul><ul><li aria-level=\"2\">Macrocephaly<\/li><\/ul><ul><li aria-level=\"2\">Vertigo<\/li><\/ul><ul><li aria-level=\"2\">Fine motor skills, reduced<\/li><\/ul><ul><li aria-level=\"2\">Fainting after exercise<\/li><\/ul><ul><li aria-level=\"2\">Epilepsy<\/li><\/ul><ul><li aria-level=\"2\">Tremor<\/li><\/ul><ul><li aria-level=\"2\">Peripheral neuropathy<\/li><\/ul><ul><li aria-level=\"2\">Dementia<\/li><\/ul><ul><li aria-level=\"1\">Presenting as Reye&#039;s syndrome: with metabolic acidosis, hypoglycemia, liver failure, neurological deterioration and coma. *2<\/li><\/ul><p>We have described two  biochemical phenotypes according to the urinary excretion of abnormal metabolites , with the same risk of developing damage to striatal without the appropriate treatment :<\/p><ul><li aria-level=\"1\">Low excretory glutaric acid ,<i> in its most carry missense mutations (missense) in at least one allele GDHC, resulting in residual enzyme activity of up to 30%<\/i>. *1 The determination of 3-O-AG is more specific because some low excretory can have normal levels of glutaric acid in urine; despite this low excretory may have fluctuations of the levels of 3-OH-AG<\/li><\/ul><ul><li aria-level=\"1\">High excretory glutaric acid  greater than 100 mmol\/mol creatinine.<\/li><\/ul><p>\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-2107\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"8\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-2107\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Symptoms  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2107\" class=\"elementor-element elementor-element-6438b38a e-con-full e-flex e-con e-child\" data-id=\"6438b38a\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1f3f0b4 elementor-widget elementor-widget-text-editor\" data-id=\"1f3f0b4\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Babies who are identified in the heel prick test (metabolic screening in the newborn) can begin the treatment before the start of the signs, and 80-90% will not develop any symptoms.<\/p><p>The severity of GA-1 varies greatly for each individual. The symptoms and treatment vary in different people with the same disease; it usually begin s in infancy or early childhood, but sometimes the symptoms begin in adolescence or early adulthood and can have many of these signs or none. In some cases, they do not develop any symptoms, even if you do not receive treatment, and only detected after diagnosing a brother or a sister, or in a casual manner.<\/p><p>If GA1 is not treated ,usually as a result of an acute illness, infection, fever, vaccine, or surgical intervention usually 80 or 90% of babies will develop neurological disorders between 3 and 36 months of age; a metabolic decompensation will  cause an acute encephalopathic crisis  with severe damage of the basal ganglia, decreased muscle tone (hypotonia), loss of motor skills and seizures that give rise to lesions of the nucleus striatum with severe secondary dystonia and sometimes  subdural and retinal hemorrhage<\/p><p>The symptoms can be difficult to evaluate:<\/p><ul><li aria-level=\"1\">About 75% of the newborns with GA1 have a large head circumference (macrocephaly), present at birth or shortly after birth.<\/li><\/ul><ul><li aria-level=\"1\">About 50% will have weak muscle tone (hypotonia).<\/li><\/ul><ul><li aria-level=\"1\">Lack of appetite<\/li><\/ul><ul><li aria-level=\"1\">Feeding problems<\/li><\/ul><ul><li aria-level=\"1\">Drowsiness<\/li><\/ul><ul><li aria-level=\"1\">Fatigue<\/li><\/ul><ul><li aria-level=\"1\">Irritability<\/li><\/ul><ul><li aria-level=\"1\">Vomiting\/nausea<\/li><\/ul><ul><li aria-level=\"1\">Fever<\/li><\/ul><ul><li aria-level=\"1\">Growth retardation<\/li><\/ul><ul><li aria-level=\"1\">Delay in the prop head<\/li><\/ul><ul><li aria-level=\"1\">Stiff muscles (spasticity)<\/li><\/ul><ul><li aria-level=\"1\">Developmental delays<\/li><\/ul><ul><li aria-level=\"1\">Delays in walking and other motor skills<\/li><\/ul><ul><li aria-level=\"1\">Learning delays<\/li><\/ul><ul><li aria-level=\"1\">Speech problems<\/li><\/ul><ul><li aria-level=\"1\">Large liver<\/li><\/ul><ul><li aria-level=\"1\">Strange behavior, nervousness<\/li><\/ul><ul><li aria-level=\"1\">Muscle spasms<\/li><\/ul><ul><li aria-level=\"1\">Lack of coordination and balance<\/li><\/ul><ul><li aria-level=\"1\">Involuntary movements of the arms and legs (<a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/dystonia.html\">dystonia)<\/a>: the basal ganglia area of the brain that helps control movement. In some children, the brain damage will occur without fever trigger. Damage to the basal ganglia, especially before 6 years of age, can cause a disruption of the complex motion, similar to cerebral palsy. The control of the movement of hands, arms, feet, legs, head, and neck can be very difficult. The movements can be jerky or stiff.<\/li><\/ul><ul><li aria-level=\"1\">Seizures: the frequency of epilepsy is increased in patients with Glutaric Acidemia type I, and in  the crisis it  may be the initial presentation symptom.<\/li><\/ul><ul><li aria-level=\"1\">There is a time during childhood there is a higher probability of subdural bleeding, which may be confused with child abuse with injury to the head.<\/li><\/ul><p>The repeated stress on the body (such as infection and fever) can worsen the symptoms<\/p><p>Some studies have shown that the intellectual capacity of a person with GA1, even if it is not treated , is not affected.<\/p><p>At six years of age and with the appropriate treatment, the risk of a encephalopathic crisis decreases.<\/p><p>In some patients, a hypotonia and dystonia  gradually develops a without any encephalopathic crisis , which is known as late-onset or insidious onset. Patients may present non specific neurological symptoms  such as headaches, vertigo, ataxic transitory gait ,reduced fine motor skills, or fainting after exercise, but not develop damage from the nucleus striatum.<\/p><p><i>Recommendation number 3<\/i><\/p><p><i>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Strong recommendation: In children with Subdural bleeding (including suspected shaken baby syndrome) and \/ or collections of bitemporal fluid that suggest frontotemporal  hypoplasia and \/ or aracnoideos cysts ,  a diagnostic study is recommended using the algorithm for the diagnostic study directed.<\/i><\/p><p><i>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/i> <i>Level of evidence Moderate SIGN 2+ 4. Consistency of evidence moderate<\/i><\/p><p><i>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/i> <i>Clinical relevance High*1<\/i><\/p><p><i>Statement 2:<\/i><\/p><p><i>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0The finding of subdural bleeding is usually accompanied by other radiological abnormalities characteristics of AG-I (for example hypoplasia frontotemporal, spaces of cerebrospinal fluid widened etc.). The isolated finding of subdural bleeding without these characteristic abnormalities is not suggestive of AG-I per se and should not lead to a diagnostic study<\/i><b><i> directed. *1<\/i><\/b><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-2108\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"9\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-2108\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Treatments  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2108\" class=\"elementor-element elementor-element-4878ba87 e-con-full e-flex e-con e-child\" data-id=\"4878ba87\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1cd90ca3 elementor-widget elementor-widget-text-editor\" data-id=\"1cd90ca3\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">The goal of the  treatment is to maintain concentrations of glutaric acid and derivatives low, which has shown to reduce the frequency of encephalopathic crises and acute movement disorders (often above 80% to 90%, now 10-20%). And consequently, in those diagnosed early, the morbidity and mortality.<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Dietary treatment: <\/span><span style=\"font-weight: 400;\">diet low in lysine, with the nutrients and enough calories for growth and development<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Supplements of carnitine<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Emergency treatment:<\/span><span style=\"font-weight: 400;\"> intensified during the intercurrents diseases (catabolism); it is effective and improves the neurological outcome in those individuals diagnosed early.<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">Treatment should be initiated when there is a great suspicion of GA1, before confirmation of the diagnosis by enzyme analysis and \/ or mutations. However, the treatment after the onset of symptoms, is less effective. The treatment is individualized, adapting to the characteristics of each child, which may be recommended for some children, for others it is not suitable. The dietary treatment is more flexible after 6 years of age and should be monitored by specialized  metabolic centers\u00a0<\/span><\/p><p><i><span style=\"font-weight: 400;\">The development and evaluation of treatment plans, the training and education of the individuals affected and their families, and to avoid adverse effects of the dietary treatment (for example, malnutrition, growth retardation) require the experience of  metabolic specialized centers ,including specialists in metabolic diseases, inherited, genetic counseling, nutritionists, nurses, physiotherapists, occupational therapists, speech therapists, psychologists, and social workers. The regular follow-up in specialized metabolic centers  significantly increases the likelihood that  the disease is asymptomatic. *1<\/span><\/i><\/p><p><span style=\"font-weight: 400;\">\u00a0<\/span><i><span style=\"font-weight: 400;\">It is suggested that early intervention with intravenous glucose, during the illness in the first two years of life, is the only intervention clearly neuroprotective in GA1*1<\/span><\/i><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-2109\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"10\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-2109\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Complications  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2109\" class=\"elementor-element elementor-element-78fa982d e-con-full e-flex e-con e-child\" data-id=\"78fa982d\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2aafc6f2 elementor-widget elementor-widget-text-editor\" data-id=\"2aafc6f2\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">The main neurological complications of the AG-I are the development of movement disorder and subdural bleeding. There is also increased frequency of epilepsy.<\/span><\/p><p><i><span style=\"font-weight: 400;\">Recommendation number 10<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Strong recommendation: neurological Complications (epilepsy, movement disorder) or neurosurgery (subdural bleeding) should be treated by a pediatric neurologist and\/or neurosurgeon, in collaboration with the specialist in metabolism.<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\">Level of evidence: moderate SIGN level 2 - 3<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\">Clinical relevance: High<\/span><\/i><\/p><p><b>\u00a0\u00a0\u00a0\u00a0\u00a0DYSTONIA<\/b><\/p><p><i><span style=\"font-weight: 400;\">Individuals who adhere to treatment recommendations rarely develop dystonia (5%), while the non-adherence to treatment increases the rate at 44% and the non-adherence to treatment of emergency increases the rate to 100%. *1<\/span><\/i><\/p><p><span style=\"font-weight: 400;\">Movement disorders in GA-I are very difficult to treat, and there is little evidence regarding the effectiveness of different drugs. Previous studies have shown that baclofen and benzodiazepines are beneficial in the majority of symptomatic patients, and is recommended for first-line treatment. The use of valproic acid should be avoided.<\/span><\/p><p><span style=\"font-weight: 400;\">Children with dystonia or severe dystonic status , may have an increased energy demand despite treatment with medications and immobility. Individuals with dystonia need intensive  dietary supervision to adapt the intake of energy and prevent catabolism. They are also at risk of aspiration pneumonia and malnutrition if they suffer orofacial dyskinesis<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Baclofen:<\/span><span style=\"font-weight: 400;\"> along with benzodiazepines, oral baclofen  most commonly used and seemingly effective for the long-term treatment of movement disorders in GA1. The baclofen-run intrathecal has been used with success in individuals with GA1 and severe dystonia . In children with axial hypotonia  the use of baclofen may be limited because it worsens the muscle tone. Along with benzodiazepines, oral baclofen (in monotherapy or combination therapy) is the most widely used  drug and apparently effective for the long-term treatment of movement disorders in AG-I, and should be used in doses according to the general recommendations. The baclofen-run intrathecal has been used with success in individuals with AG-I and severe dystonia. In younger children, with a prominent axial hypotonia , the use of baclofen may be limited by the deterioration of reduced muscle tone<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Benzodiazepines:<\/span><span style=\"font-weight: 400;\"> diazepam and clonazepam. In individuals with variable symptoms, the daily dose can be adjusted within a certain range; sometimes treatment may be necessary intermittently. Zopiclone has shown positive effects in some individuals affected by reducing the proportion of movement disorders and the general muscle tone. If the treatment with baclofen or benzodiazepines is not effective, or if adverse effects develop second-line anticholinergic drugs should be considered .Diazepam  and clonazepam have shown positive effects in more than 90% of symptomatic individuals. The doses should be administered according to the general recommendations. In individuals with variable symptoms, the daily dose can be adjusted within a certain range. <\/span><i><span style=\"font-weight: 400;\">To prevent tachyphylaxis treatment can be<\/span><\/i><span style=\"font-weight: 400;\">required intermittently .Zopiclone, a cyclopyrrolone used as a hypnotic drug mainly in dystonia non-metabolic, has shown positive effects in some individuals affected by reducing the proportion of movement disorders hyperkinetic and overall muscle tone, due to its qualities, sedative, hypnotic, anxiolytic and muscle relaxant. In contrast with other benzodiazepines, its pharmacodynamic effect is mediated by the receptor for gamma-aminobutyric A (GABA-A subunits BZ1 and BZ2) and the modulation of the chloride channel with a low risk of developing tolerance and addiction. Individuals treated are more relaxed and awake during the day, as they are less affected by movement disorder during the night. It is important to tailor the dose with caution and a step by step reduction , and preferably in the regime of hospitalization. If the treatment with baclofen or benzodiazepines is not effective, or if they occur adverse effects,  second-line anticholinergic drugs should be considered<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Anticholinergic drugs:<\/span><span style=\"font-weight: 400;\"> trihexyphenidyl may be effective in the treatment of dystonia, especially in adolescents and adults, but it can also be effective in children if the dose is increased gradually. However, adverse effects occur frequently (for example transient symptoms such as blurred vision and dry mouth, or persistent symptoms such as memory loss and confusion), and may worsen hyperkinetic dystonia. Adults should have regular follow-up of ocular tonometry.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Botulinum toxin:<\/span><span style=\"font-weight: 400;\"> can help to prevent hip dislocation and to reduce the dystonia of the limbs. Some individuals may develop antibodies against the toxin, and may require cessation of treatment. Is usually given once every 3-6 months.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Drugs with side effects:<\/span><span style=\"font-weight: 400;\">none of these drugs should be used for dystonia in GA1.<\/span><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">The vigabatrin may cause defects in the peripheral visual field<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Valproate can affect negatively the proportion of mitochondrial acetyl-CoA\/CoA<\/span><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Medications  with no effect on dystonia:<\/span><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Carbamazepine<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">L-dopa<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Amantadine<\/span><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neurosurgery:<\/span><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Stereotactic surgery (pallidotomy) has been carried out in three individuals with AG-I severely dystonic. In two of them, the clinical outcome was poor, however the third showed improvement in the short-term. There have been No published data on the long-term outcome after pallidotomy.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Deep brain stimulation has been carried out with some positive results.<\/span><\/li><\/ul><p><b>\u00a0\u00a0\u00a0\u00a0SUBDURAL BLEEDING<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/p><p><span style=\"font-weight: 400;\">In some cases, subdural  hemorrhages have been observed even in those diagnosed by neonatal screening. They can appear spontaneously or with mild trauma, important to keep in mind before the suspicion of abuse.<\/span><\/p><p><b><i>Recommendation number 4<\/i><\/b><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Strong recommendation: The subdural bleeding is usually found in combination with other neuroradiological abnormalities typical of GA-I  frontotemporal hypoplasia , expanded spaces of CSF, etc., The subdural bleeding isolated without these characteristic abnormalities per se, is not suggestive of GA-I and does not lead to a diagnostic<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\">Level of evidence from high to moderate SIGN 2++ 4. Consistency of evidence moderate<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\">Clinical relevance high *1<\/span><\/i><\/p><p><span style=\"font-weight: 400;\"><br \/><\/span><b>\u00a0 \u00a0 \u00a0 EPILEPSY<\/b><\/p><p><span style=\"font-weight: 400;\">The risk of epilepsy is increased in AG-I, and has been described in 7% of patients. The crisis may be the first or only symptom of the disease. The isolated seizures can occur during the encephalopathic crises We also have evaluated cases of infantile spasms and hipsarrtimia in the absence of encephalopathy. The dystonic movements may be misinterpreted as seizures. No study has analyzed the efficacy of antiepileptic drugs in AG-I. however, as previously mentioned, valproate and vigabatrin should be avoided. The choice of antiepileptic drug should derive from the semiology of the seizures and of the specific patterns of the electroencephalogram.<\/span><\/p><p><b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CHRONIC RENAL FAILURE<\/b><\/p><p><span style=\"font-weight: 400;\">There is the possibility of chronic renal failure in 20-25% of adults aged 20 years and with a lower frequency of acute renal failure due to nephrotic syndrome, hemolytic uremic syndrome. *2<\/span><\/p><p><b>\u00a0\u00a0\u00a0BRAIN CANCER<\/b><\/p><p><span style=\"font-weight: 400;\">There is literature on cases of children and adults with malignancies of the brain, but there is no evidence that those affected with AG1 are more susceptible to this type of tumors. *2<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-21010\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"11\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-21010\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Diagnosis  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-21010\" class=\"elementor-element elementor-element-c2bca52 e-con-full e-flex e-con e-child\" data-id=\"c2bca52\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-47928e77 elementor-widget elementor-widget-text-editor\" data-id=\"47928e77\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">The early diagnosis allows a reduction of those affected who are suffering encephalopathic crisis , allowing genetic counselling for the prevention or early detection of new cases, family members.<\/span><\/p><p><span style=\"font-weight: 400;\">If the results suggest a positive diagnosis, treatment  must be started without delay the , without waiting for the genetic analysis.<\/span><\/p><p><span style=\"font-weight: 400;\">When you get a definitive diagnosis, the families should receive intensive training by a specialist in metabolic diseases, in the diagnosis, treatment, prognosis, in the dietary management and pharmacotherapy to start of maintenance treatment.<\/span><\/p><p><span style=\"font-weight: 400;\">The long-term management should be performed in a centre with a metabolic specialist (CSUR of reference for this disease) in collaboration with children's hospital , pediatrics center of health (vaccinations, routine checks), care facilities or skilled rehabilitation, support groups for families of individuals with GA1 (exchange of experience)...it Would be appropriate for the families received the written information with details regarding the emergency treatment and the metabolic center's contact.  It is important to recognize the symptoms that indicate catabolism and should be given an introduction to the treatment of emergency in a staggered manner.<\/span><\/p><p><i><span style=\"font-weight: 400;\">Recommendation number 1<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Strong recommendation: When you are suspect of GA-I, the studies diagnosis, the development of treatment plans, the appropriate information and training of the affected people and their families, should take place in specialized centers in metabolism. Affected individuals should be transferred to these centers without delay.<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\">Level of evidence: A study (SIGN level 2 ++) has shown positive effect of monitoring by a central metabolic (Heringer et al. 2010)<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\">Clinical relevance: High *1<\/span><\/i><\/p><p><b>\u00a0\u00a0\u00a0SYMPTOMATIC<\/b><\/p><p><span style=\"font-weight: 400;\">The diagnosis should be suspected on the basis of:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Clinical findings:<\/span><span style=\"font-weight: 400;\"> macrocephaly, encephalopathy, damage to the basal ganglia, alteration of white matter, movement disorders (dystonia, chorea), hemorrhages, subdural and retinal, and high concentrations of acid glut\u00e1rico, acid-3-hidroxiglut\u00e1rico and glutarilcarnitina in body fluids.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Findings neuroradiological:<\/span><span style=\"font-weight: 400;\"> operculum very open, lesions in the basal ganglia, enlargement of the sylvian fissure, increase in the subarachnoid space in the temporal lobes, alteration of the intensity of the signal in the sequences T2 in basal ganglia and white matter, collections, subdural, enlargement of the cisterns mesencephalic, typical images of frontotemporal atrophy bilateral (\u201cbat wings\u201d in the TAC) and by alterations of the white matter in varying degrees in the magnetic resonance imaging of the brain.<\/span><ul><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Hypoplasia front-opercula-temporary cysts bitemporal, pseudocysts subepepndimarios, subdural collections  delay in myelination, signs of leukoencephalopathy and areas of increased signal in the striatum.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">During the encephalopathic crisis abnormalities appear in the striatum associated with abnormalities of signal in the putamen, caudate, pallidum, and periventricular white matter.<\/span><\/li><\/ul><\/li><\/ul><p><span style=\"font-weight: 400;\">It is confirmed by enzymatic activity significantly reduced and\/or by the detection of pathogenic mutations in both alleles of GCDH.<\/span><\/p><p><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0<\/span><b>PRESYMPTOMATIC<\/b><\/p><p><i><span style=\"font-weight: 400;\">The two subtypes have a similar clinical course and a high risk of developing damage to the striatal core if they are not treated. A neuroradiological study recently revealed a high frequency of abnormalities in the white matter that progress with age, and high concentrations of intracerebral glutaric acid and acid 3 hydroxy-glutaric detected in vivo by spectroscopy magnetic resonance  of protons in high excretory. However, the clinical  relevance of these observations needs to be determined. *1<\/span><\/i><\/p><p><span style=\"font-weight: 400;\">Thanks to newborn screening or testing of the heel are identified elevated levels of glutarilcarnitine are identified (C5D5) , using drops of blood on paper analyzed by tandem mass spectrometry.<\/span><\/p><p><span style=\"font-weight: 400;\">If you have a positive value (C5D5 above the level of court), it is confirmed by analysis in urine of organic acids, with elevation of the glutaric acid (AG), 3-hidroxiglutaric  (3-OH-GA), acid glutac\u00f3nico and glutarilcarnitina; through a quantitative analysis of organic acids in urine, using gas chromatography-mass spectrometry and\/or tandem mass spectrometry (acylcarnitines).<\/span><\/p><p><span style=\"font-weight: 400;\">The presymptomatic detection is done through programs of neonatal routine screening implemented in some countries, as in Spain.<\/span><\/p><p><span style=\"font-weight: 400;\">The diagnosis is confirmed by detection of mutations in the two alleles of GCDH or the measurement of the enzymatic activity in fibroblasts or leukocytes (significantly reduced) that has a sensitivity of 98-99%.<\/span><\/p><p><span style=\"font-weight: 400;\">The enzymatic activity helps the diagnosis in case the genetic study is negative and the biochemistry or neuroradiological studies suggest the disease.<\/span><\/p><p><span style=\"font-weight: 400;\">The high excretory have an enzymatic activity 0-3% and the low excretory up to 30%.<\/span><\/p><p><i><span style=\"font-weight: 400;\">If only one or no mutation causing the disease are found  but there are other biochemical characteristics and \/ or neuroradiological suggestive OF Glutaric Acidemia type I, the activity of GCDH in leukocytes or fibroblasts must be determined . An activity significantly reduced confirms the diagnosis, whereas a normal activity (or values in the range of carriers heterozygous) excludes it. *1<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">Recommendation 2<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Strong recommendation: A positive result of the neonatal screening and clinical data, biochemical, and \/ or neuroradiological suggestive of GA1 should be confirmed by diagnostic study, including quantitative analysis of GA and 3-OH-GA in urine and \/ or blood, mutation of the gene GCDH, and \/ or enzymatic analysis GCDH in leukocytes or fibroblasts.<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\">Level of evidence Moderate SIGN 2+ 4.Consistency of evidence high<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\">Clinical relevance is High.*1<\/span><\/i><\/p><p><span style=\"font-weight: 400;\">The Glutaric  Acidemia type I is a reasonable candidate for neonatal screening, and has been included in the panels of neonatal screening by tandem mass spectrometry in many countries around the world.<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">It has led to an improvement in the evolution of the disease, preventing associated disability, preventing nerve damage is irreversible and decreasing mortality.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neonatal diagnosis and onset of treatment increase the likelihood of a course of an asymptomatic disease<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Provides great information to families thanks to the genetic council<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">The mass neonatal screening in the population of Glutaric Acidemia type I is carried out through the analysis of acylcarnitine by tandem mass spectrometry in drops of dried blood, which has increased the sensitivity and reduced the false positives.<\/span><\/p><p><span style=\"font-weight: 400;\">In spite of this, it does  not identify all the patients, especially the low excretory , so a negative result does not exclude the diagnosis. The low excretory present normal levels or slightly elevated, and may not be detected, since the sensitivity of screening for this phenotype is 84% *2<\/span><\/p><p><i><span style=\"font-weight: 400;\">Statement 1:<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0The Glutaric  acidemia type-I should be included in the differential diagnosis if the newborn screening sample (1) carnitine free decreased or (2) high glutarilcarnitine but confirmation of the diagnosis in the child is negative or you can\u00b4t find another appropriate explanation <\/span><\/i> <i><span style=\"font-weight: 400;\">to the abnormal initial screening<\/span><\/i><\/p><p><b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0PRENATAL:<\/b><\/p><p><span style=\"font-weight: 400;\">Can be done in families at risk, although its indication is questionable.<\/span><\/p><p><span style=\"font-weight: 400;\">The prenatal test  can be done by genetic analysis and the enzyme GCDH of chorionic villus samples in 8-10 weeks, or by measuring the levels of glutaric acid in the amniotic fluid at 16-20 weeks in at-risk families.<\/span><\/p><p><span style=\"font-weight: 400;\">It is necessary to have a genetic test to confirm the prenatal diagnosis.<\/span><\/p><p><b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0DIFFERENTIAL<\/b><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><i><span style=\"font-weight: 400;\">Macrocephaly benign family, communicating hydrocephalus<\/span><\/i><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><i><span style=\"font-weight: 400;\">Metabolic disorders associated with macrocephaly (for example, Canavan disease)<\/span><\/i><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><i><span style=\"font-weight: 400;\">Transmissible metabolic disorders that affect the basal ganglia (for example Leigh syndrome among mitochondrial diseases)<\/span><\/i><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><i><span style=\"font-weight: 400;\">Errors of metabolism that cause stroke as the orotic organic classic, disorders of the urea cycle, and mitochondrial diseases (for example syndrome MELAS \u2013 myopathy, encephalopathy, lactic acidosis, and episodes like stroke)<\/span><\/i><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><i><span style=\"font-weight: 400;\">Causes metabolic damage of the nucleus striatum ( Mycoplasma pneumoniae infection)<\/span><\/i><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><i><span style=\"font-weight: 400;\">Transmissible non-metabolic diseases (encephalitis, meningitis, intoxication)<\/span><\/i><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><i><span style=\"font-weight: 400;\">Cerebral palsy child or child abuse*1<\/span><\/i><\/li><\/ul><p><b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0GA1 MATERNAL<\/b><\/p><p><span style=\"font-weight: 400;\">The positive neonatal screening , in some cases  return to normal levels in the newborn and are found in the mother, and the levels of carnitine low or glutarilcarnitina increased.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-21011\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"12\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-21011\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> How it is inherited  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-21011\" class=\"elementor-element elementor-element-2a86b377 e-con-full e-flex e-con e-child\" data-id=\"2a86b377\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-408c89e7 elementor-widget elementor-widget-text-editor\" data-id=\"408c89e7\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">The chromosomes of the nucleus of human cells, carry the genetic information of every person. 46 chromosomes, distributed in 23 pairs, which are numbered from 1 through 22 and the sex chromosomes are designated X and Y. males have one X chromosome and a y, the women have two x chromosomes.<\/span><\/p><p><span style=\"font-weight: 400;\">Each chromosome has a short arm called p <\/span><i><span style=\"font-weight: 400;\">p <\/span><\/i><span style=\"font-weight: 400;\">and a long arm called q <\/span><i><span style=\"font-weight: 400;\">q<\/span><\/i><span style=\"font-weight: 400;\">. Chromosomes are further sub-divided into many bands that are numbered, that specify the location of the genes that are present on each chromosome.<\/span><\/p><p><span style=\"font-weight: 400;\">The<\/span><i><span style=\"font-weight: 400;\"> Genetic recessive disorders<\/span><\/i><span style=\"font-weight: 400;\"> occur when an individual inherits an abnormal gene for the same trait from each parent. The risk is the same for men and women.<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The risk for two carrier parents to pass the defective gene and, therefore, have an affected child is 25% with each pregnancy.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The risk of having a child who is a carrier like the parents, receives one normal gene and one gene for the disease, is of 50% with each pregnancy.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The probability that a child will receive normal genes from both parents and be genetically normal for that particular trait is 25%.<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">In people with GA-1, none of the genes that produce the enzyme glutaril-CoA dehydrogenase works well. An altered gene that causes the disease  is inherited from each parent<\/span><\/p><p><span style=\"font-weight: 400;\">Parents who are close relatives (consanguineous) have a higher chance than the parents who are not related, both have the same abnormal gene, which increases the risk of having children with a recessive genetic disorder<\/span><\/p><p><span style=\"font-weight: 400;\">It is important to inform family members who may be carriers as there is the possibility that they may also have children with GA-1.<\/span><\/p><p><span style=\"font-weight: 400;\">We have genetic counseling available. The genetic counselor will be able to clarify the doubts about how the disease is inherited, what alternatives you have in future pregnancies, and what tests are available for the rest of the family<\/span><\/p><p><span style=\"font-weight: 400;\">The genetic study to detect the GA-1 can be performed from a blood sample. Genetic testing, also called DNA analysis, looks for changes in the pair of 19 genes that cause the GA-1.<\/span><\/p><p><i><span style=\"font-weight: 400;\">Until now 187 pathogenic mutations have been published and are in the database of genetic mutations in humans.*1 ( in European population, the most common is R402W).<\/span><\/i><\/p><p><span style=\"font-weight: 400;\">If mutations were found in both genes,  DNA testing can be done (chorionic villus sampling or amniocentesis) for future pregnancies. Parents can choose to do studies of screening during pregnancy or wait until the birth. A genetic counselor will be able to explain the alternatives that you have and clarify all your doubts about the tests that can be performed on the baby before or after birth.<\/span><\/p><p><span style=\"font-weight: 400;\">The brothers of a baby with GA-1 are likely to be carriers or have the disease, even if they have not had symptoms; therefore, it is important to determine if you have GA-1 to avoid serious health problems. Consult your specialist or genetic counselor about what you should do.<\/span><\/p><p><b>\u00a0\u00a0\u00a0\u00a0GA1 + HEALTHY:<\/b><\/p><p><span style=\"font-weight: 400;\">\u00a0If a person with GA1 and a person who has two normal copies of the gene GCDH have children, each child will be a carrier of GA1.<\/span><\/p><p><b>CARRIER + CARRIER\u00a0<\/b><\/p><p><span style=\"font-weight: 400;\">When both parents are carriers:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">There is a 25% chance in each pregnancy that the child will have GA -1.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">50% chance that the child will be a carrier, as are their parents.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">25% chance that the two genes play properly its function<\/span><\/li><\/ul><p><b>\u00a0\u00a0\u00a0GA1 + CARRIER:<\/b><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">If a person with GA1 and a carrier of GA1 has children, each child has a:<\/span><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">50% chance of having GA1<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">50% chance of being a carrier<\/span><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-21012\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"13\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-21012\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Follow-up  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-21012\" class=\"elementor-element elementor-element-2be946d4 e-con-full e-flex e-con e-child\" data-id=\"2be946d4\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-428a2110 elementor-widget elementor-widget-text-editor\" data-id=\"428a2110\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">The regular follow-up  in metabolism specialized centers significantly increases the likelihood that the course of the disease will be asymptomatic. The treatment should be tailored specifically to each patient. The objective is to evaluate the effectiveness of treatment and to identify complications or side effects.<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Ensure the adherence to the treatment recommendations: essential to prevent significant neurological damage<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Anthropometric parameters,<\/span><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Weight<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Height<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Head circumference<\/span><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Developmental milestones.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neurological assessment<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Psychological Tests specific<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Parameters diet.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Consultations with other specialties<\/span><\/li><\/ul><ul><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Neuropediatras<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Psychologists<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Physiotherapists<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Occupational therapist<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Social work<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Nutritionists<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Dietitians<\/span><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-21013\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"14\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-21013\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> International recommendations 2023 <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-21013\" class=\"elementor-element elementor-element-1e6ca2dc e-con-full e-flex e-con e-child\" data-id=\"1e6ca2dc\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7feea19a elementor-widget elementor-widget-text-editor\" data-id=\"7feea19a\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">\u00a0Strong recommendation: The therapeutic effectiveness should be monitored with regular follow-up and intensified to any age if the symptoms progress, manifest new symptoms (disease or therapy-related), or is suspected of lack of adherence to treatment recommendations. See Recommendations 13-17.<\/span><\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Level of evidence: Moderate (SIGN 2++ to 3)<\/span><\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Clinical relevance: Depending on the end point in particular. *1<\/span><\/span><\/span><\/i><\/p><p><b><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Clinical follow-up after head injuries: <\/span><\/span><\/b><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Even with the recommended treatment and in patients without macrocephaly, the subdural bleeding can occur after a minor head injury. Recent research has revealed a higher incidence in the high excretory.<\/span><\/span><\/span><\/p><p><b><i><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Recommendation number 12<\/span><\/span><\/i><\/b><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Recommendation: individuals with AG-I should be hospitalized and clinical supervision close after a head injury.<\/span><\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Level of evidence: Low (SIGN 3 to 4)<\/span><\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Clinical relevance: High<\/span><\/span><\/span><\/i><\/p><p><b><i><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Statement number 4:<\/span><\/span><\/i><\/b><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">The psychosocial effects of the diagnosis and treatment of the AG-I should be evaluated both in affected individuals and their families as part of the routine follow-up.<\/span><\/span><\/span><\/i><\/p><p><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">\u00a0ANALYTICAL:<\/span><\/span><\/p><p><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Your child will undergo regular blood tests to measure their levels of amino acids. Urine tests may also be done. It may be necessary to adjust the diet and medications your child in function of the results of analysis of blood and urine.<\/span><\/span><\/p><p><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">During the first year follow up tends to be quarterly as a minimum and up to 6 years semi-annual.<\/span><\/span><\/p><p><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">You should take blood tests periodically to measure the level of amino acids together with analysis of urine. The diet and the medication your child may need adjustments according to the results of the analysis of blood and urine. <\/span><\/span><br \/><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">The monitoring needs to be strengthened at any age if there are new complications or lack of adherence to treatment.<\/span><\/span><\/p><ul><li aria-level=\"1\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Organic acids.\u00a0\u00a0<\/span><\/span><\/li><\/ul><ul><li aria-level=\"1\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Amino acids: help to ensure that you receive a proper diet.<\/span><\/span><\/li><\/ul><ul><li aria-level=\"1\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">The levels of lysine should be maintained within the normal range.<\/span><\/span><\/li><\/ul><ul><li aria-level=\"1\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">If you suspect a deficiency of tryptophan, should be measured using liquid chromatography-high-efficiency liquid chromatography (HPLC) or mass spectrometry in tandem.<\/span><\/span><\/li><\/ul><ul><li aria-level=\"1\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Carnitine: can be evaluated using liquid chromatography-high-efficiency liquid chromatography (HPLC) or mass spectrometry in tandem, and provides information on treatment adherence, must be at the upper limit of normal.<\/span><\/span><\/li><\/ul><ul><li aria-level=\"1\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Renal function. A recent study found that some adolescents and adults with AG-I have chronic renal failure. Therefore, you should follow the kidney function in adults with AG-I. In a mouse model of AG-I has been observed tubular dysfunction kidney after a test with high protein.<\/span><\/span><\/li><\/ul><ul><li aria-level=\"1\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Follow-up biochemical during acute illness: there is a risk of dehydration and electrolyte imbalance during periods of recurrent vomiting, diarrhea, and\/or intake reduced nutrients and fluids, increasing the risk of a crisis encefalop\u00e1tica.<\/span><\/span><\/li><\/ul><ul><li aria-level=\"2\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Gas in blood<\/span><\/span><\/li><\/ul><ul><li aria-level=\"2\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Electrolytes<\/span><\/span><\/li><\/ul><ul><li aria-level=\"2\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Creatine kinase<\/span><\/span><\/li><\/ul><ul><li aria-level=\"1\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Profile of acylcarnitine: it does not provide information relevant to the monitoring of treatment.<\/span><\/span><\/li><\/ul><p><i><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Recommendation number 13<\/span><\/span><\/i><\/p><p><i><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Recommendation: The analysis of urinary concentrations of acid glut\u00e1rico and 3-hidroxiglut\u00e1rico should not be used for treatment monitoring.<\/span><\/span><\/i><\/p><p><i>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/i> <i><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Level of evidence: Moderate (SIGN 2+ 3)<\/span><\/span><\/i><\/p><p><i>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/i> <i><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Clinical relevance: Low<\/span><\/span><\/i><\/p><p><i><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Recommendation number 14<\/span><\/span><\/i><\/p><p><i><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Strong recommendation: The amount of amino acids should be quantified frequently in plasma on infants and children with a diet low in lysine (ideally 3-4 hours after eating). The concentration of lysine and other essential amino acids must be kept within the normal range.<\/span><\/span><\/i><\/p><p><i>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/i> <i><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Level of evidence: Moderate (SIGN 2+ 4). The consistency of the evidence is high.<\/span><\/span><\/i><\/p><p><i>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/i> <i><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Clinical relevance: High<\/span><\/span><\/i><\/p><p><i><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Recommendation number 15<\/span><\/span><\/i><\/p><p><i><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Recommendation: the levels of carnitine in plasma in all individuals with AG-1 should be followed frequently<\/span><\/span><\/i><\/p><p><i>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/i> <i><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Level of evidence: Moderate (SIGN 2+ 4). The consistency of the evidence is moderate.<\/span><\/span><\/i><\/p><p><i>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/i> <i><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Clinical relevance: High<\/span><\/span><\/i><\/p><p><b><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">\u00a0VACCINES IN GA1<\/span><\/span><\/b><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Patients with chronic diseases should comply with a calendar of vaccinations optimized.<\/span><\/span><\/span><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">The optimization of the vaccination in all cohabitants of the chronically ill,  should always be considered, both the vaccines included in the official calendar and other non-systematic as the annual flu, and chicken pox.<\/span><\/span><\/span><\/p><p><span style=\"font-weight: 400;\">\u00a0<\/span><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">If, after the vaccine no symptoms are displayed , the patient can continue with their treatment and usual diet.<\/span><\/span><\/span><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">If we face a situation of fever &gt;38 \u00b0 C, you must decrease the consumption of natural proteins in the diet, following the emergency regimen facilitated by the specialists. Stay in contact with their medical specialists in metabolic diseases.<\/span><\/span><\/span><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">You can access the <\/span><\/span><\/span><a href=\"https:\/\/www.familiasga.com\/vacunas-en-aciduria-glutarica-tipo-1\/\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">document produced by Dr. Silvia Chumillas<\/span><\/span><\/span><\/a><\/p><p><b><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">\u00a0WHEN YOU GET IN TOUCH WITH THE SPECIALIST<\/span><\/span><\/b><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">For some babies and children, even a mild illness can lead to a crisis metabolic, so the contact with your specialist in these cases it is important to:<\/span><\/span><\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Loss of appetite<\/span><\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Low energy, weakness, or extreme drowsiness.<\/span><\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Vomiting<\/span><\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Fever<\/span><\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Infection or disease<\/span><\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Alteration of behavior or personality changes<\/span><\/span><\/span><\/li><\/ul><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Children who are sick often don&#039;t want to eat. If they can&#039;t eat, or show the above signs, you should go to the hospital, prevention is the best treatment in AG1. It is advisable to have a written emergency protocol and carry it with you each time you go to the hospital, the emergency services tend not to be familiar with the disease and the protocol is the guide in which you should rely.<\/span><\/span><\/span><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Studies neuroradiological should be performed if there are signs of neurological deterioration.<\/span><\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Brain concentrations of acid glut\u00e1rico (GA) and 3-hydroxy-glut\u00e1rico can be detected by magnetic resonance spectroscopy, non-invasive in vivo (it is not clear whether this method can be used for long-term monitoring and adjustment of treatment).<\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">The  magnetic resonance imaging (MRI)  has shown a characteristic pattern of alterations of gray and white matter , and vast spaces of cerebrospinal fluid in the GA1 (but are highly variable and dynamic). MRI with diffusion sequences enable the detection of lesions of the nucleus striatum more accurately and earlier than the TAC. The RM series can allow for a greater understanding of the neuropathogenesis observing its evolution over time, however, it is not considered essential for the follow-up.<\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">The ultrasound head can detect abnormalities in the structure of the brain (pe last trimester of pregnancy).<\/span><\/span><\/li><\/ul><p><i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Notably, they have been presented isolated cases of brain lesions, neoplastic in individuals not treated with disease of late onset and an adult. However it is not clear whether these findings are coincidental or whether adults with Argininosuccinic Acidemia type I have an increased risk of neoplasms of the brain. *1<\/span><\/span><\/i><\/p><p><span style=\"font-weight: 400;\">\u00a0<\/span><i><span style=\"font-weight: 400;\">\u00a0 \u00a0\u00a0<\/span><\/i><i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Recommendation number 16<\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Recommendation: studies neuroradiological should be done if they occur signs of neurological deterioration<\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Level of evidence: Moderate (SIGN 2+ 4). Consistency of evidence moderate<\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Clinical relevance: Moderate to high<\/span><\/span><\/i><\/p><p><b><span style=\"vertical-align: inherit;\">NEUROCOGNITIVE ASSESSMENT<\/span><\/b><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Individuals with GA1 can be at risk of impaired cognitive function. So you should perform a regular assessment of neuropsychological functions:<\/span><\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Intelligence<\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Development learning disability<\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Engine functions<\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Fine motor skills<\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Gross motor skills<\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Language (coefficient of development in young children)<\/span><\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">\u00a0<\/span><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">It has also been reported cognitive impairment in individuals with AG-I of late start.<\/span><\/span><\/p><p><i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Recommendation number 17<\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Recommendation: should Be evaluated regularly to neuropsychological functions (intelligence\/coefficient of development, motor function and language) to detect deficit-specific early and thus allowing the start of intervention strategies that are appropriate.<\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Level of evidence (SIGN 2+ 3). Consistency of the evidence to moderate.<\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">Clinical relevance:High<\/span><\/span><\/i><\/p><p><b><span style=\"vertical-align: inherit;\">TRANSITION TO ADULT<\/span><\/b><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">The transition from pediatrics to adult medicine for adolescents and young adults is essential for the long-term management and must be very well organized, planned, continuous and interdisciplinary.<\/span><\/span><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">There are No protocols for the transition but a good start can be to see to those affected by the specialist adult and pediatrician, nutritionist, psychologist and social worker, and later to continue independently.<\/span><\/span><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">At the time of puberty and the beginning of adulthood there is a lot of risk of non-adherence to treatment, which may negatively affect the clinical outcome. It is essential to continued monitoring by a center of specialized metabolism by lack of experience in this field.<\/span><\/span><\/p><p><b><span style=\"vertical-align: inherit;\">QUALITY OF LIFE<\/span><\/b><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">The assessment of psychosocial factors and the quality of life of those affected and their families is an important part of the long-term management. The impact of the disease can be a great burden to the family when they are children, so that their ability to deal with the disease is very important in the quality of life of the patient.<\/span><\/span><\/p><p><b><span style=\"vertical-align: inherit;\">Pregnancy<\/span><\/b><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\">The management of pregnancy should be supervised by an interdisciplinary team. There is No scientific evidence or clinical experience enough about the effectiveness or need for emergency treatment during the peripartum period, and no recommendations can be made. There have been published cases of a clinical course without complications for the mother and the child in women who have received emergency treatment during the peripartum period, as well as in women who received no specific therapy. However, for surgical procedures such as caesarean sections should be considered the recommendation number 9 as valid.<\/span><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-21014\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"15\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-21014\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Protocols and guidelines  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-21014\" class=\"elementor-element elementor-element-4f1846a3 e-con-full e-flex e-con e-child\" data-id=\"4f1846a3\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-244260b7 elementor-widget elementor-widget-text-editor\" data-id=\"244260b7\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Studies neuroradiological should be performed if there are signs of neurological deterioration.<\/span><\/span><\/span><\/span><\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Brain concentrations of acid glut\u00e1rico (GA) and 3-hydroxy-glut\u00e1rico can be detected by magnetic resonance spectroscopy, non-invasive in vivo (it is not clear whether this method can be used for long-term monitoring and adjustment of treatment).<\/span><\/span><\/span><\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">The  magnetic resonance imaging (MRI)  has shown a characteristic pattern of alterations of gray and white matter , and vast spaces of cerebrospinal fluid in the GA1 (but are highly variable and dynamic). MRI with diffusion sequences enable the detection of lesions of the nucleus striatum more accurately and earlier than the TAC. The RM series can allow for a greater understanding of the neuropathogenesis observing its evolution over time, however, it is not considered essential for the follow-up.<\/span><\/span><\/span><\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">The ultrasound head can detect abnormalities in the structure of the brain (pe last trimester of pregnancy).<\/span><\/span><\/span><\/span><\/span><\/li><\/ul><p><i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Notably, they have been presented isolated cases of brain lesions, neoplastic in individuals not treated with disease of late onset and an adult. However it is not clear whether these findings are coincidental or whether adults with Argininosuccinic Acidemia type I have an increased risk of neoplasms of the brain. *1<\/span><\/span><\/span><\/span><\/span><\/i><\/p><p><span style=\"font-weight: 400;\">\u00a0<\/span><i><span style=\"font-weight: 400;\">R<\/span><\/i><i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">ecomendaci\u00f3n number 16<\/span><\/span><\/span><\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Recommendation: studies neuroradiological should be done if they occur signs of neurological deterioration<\/span><\/span><\/span><\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Level of evidence: Moderate (SIGN 2+ 4). Consistency of evidence moderate<\/span><\/span><\/span><\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Clinical relevance: Moderate to high<\/span><\/span><\/span><\/span><\/span><\/i><\/p><p><b><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">NEUROCOGNITIVE ASSESSMENT<\/span><\/span><\/span><\/span><\/b><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Individuals with GA1 can be at risk of impaired cognitive function. So you should perform a regular assessment of neuropsychological functions:<\/span><\/span><\/span><\/span><\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Intelligence<\/span><\/span><\/span><\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Development learning disability<\/span><\/span><\/span><\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Engine functions<\/span><\/span><\/span><\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Fine motor skills<\/span><\/span><\/span><\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Gross motor skills<\/span><\/span><\/span><\/span><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Language (coefficient of development in young children)<\/span><\/span><\/span><\/span><\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">\u00a0<\/span><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">It has also been reported cognitive impairment in individuals with AG-I of late start.<\/span><\/span><\/span><\/span><\/span><\/p><p><span style=\"font-weight: 400;\">\u00a0<\/span><i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Recommendation number 17<\/span><\/span><\/span><\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Recommendation: should Be evaluated regularly to neuropsychological functions (intelligence\/coefficient of development, motor function and language) to detect deficit-specific early and thus allowing the start of intervention strategies that are appropriate.<\/span><\/span><\/span><\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Level of evidence (SIGN 2+ 3). Consistency of the evidence to moderate.<\/span><\/span><\/span><\/span><\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/i> <i><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Clinical relevance:High<\/span><\/span><\/span><\/span><\/span><\/i><\/p><p><b><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">TRANSITION TO ADULT<\/span><\/span><\/span><\/span><\/b><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">The transition from pediatrics to adult medicine for adolescents and young adults is essential for the long-term management and must be very well organized, planned, continuous and interdisciplinary.<\/span><\/span><\/span><\/span><\/span><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">There are No protocols for the transition but a good start can be to see to those affected by the specialist adult and pediatrician, nutritionist, psychologist and social worker, and later to continue independently.<\/span><\/span><\/span><\/span><\/span><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">At the time of puberty and the beginning of adulthood there is a lot of risk of non-adherence to treatment, which may negatively affect the clinical outcome. It is essential to continued monitoring by a center of specialized metabolism by lack of experience in this field.<\/span><\/span><\/span><\/span><\/span><\/p><p><b><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">QUALITY OF LIFE<\/span><\/span><\/span><\/span><\/b><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">The assessment of psychosocial factors and the quality of life of those affected and their families is an important part of the long-term management. The impact of the disease can be a great burden to the family when they are children, so that their ability to deal with the disease is very important in the quality of life of the patient.<\/span><\/span><\/span><\/span><\/span><\/p><p><b><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">Pregnancy<\/span><\/span><\/span><\/span><\/b><\/p><p><span style=\"font-weight: 400;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\"><span style=\"vertical-align: inherit;\">The management of pregnancy should be supervised by an interdisciplinary team. There is No scientific evidence or clinical experience enough about the effectiveness or need for emergency treatment during the peripartum period, and no recommendations can be made. There have been published cases of a clinical course without complications for the mother and the child in women who have received emergency treatment during the peripartum period, as well as in women who received no specific therapy. However, for surgical procedures such as caesarean sections should be considered the recommendation number 9 as valid.<\/span><\/span><\/span><\/span><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-21015\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"16\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-21015\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Bibliography  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-21015\" class=\"elementor-element elementor-element-6e7813b0 e-con-full e-flex e-con e-child\" data-id=\"6e7813b0\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-57652368 elementor-widget elementor-widget-text-editor\" data-id=\"57652368\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.omim.org\/entry\/231680\"><span style=\"font-weight: 400;\">OMIM<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"http:\/\/evm.health2media.com\/#\/detail-view\/disorder\/2\/101\"><span style=\"font-weight: 400;\">VADEMECUM METABOLICUM<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.rarecommons.org\/es\"><span style=\"font-weight: 400;\">RARE COMMONS<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.newbornscreening.info\/spanish\/parent\/Organic_acid\/GA2.html\"><span style=\"font-weight: 400;\">NEWBORNSCREENING INFO<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/ghr.nlm.nih.gov\/condition\/glutaric-acidemia-type-ii#definition\"><span style=\"font-weight: 400;\">NIH<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/sites\/default\/files\/deficiencia_mad_es.pdf\"><span style=\"font-weight: 400;\">Guide Metabolic<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.rarecommons.org\/es\/actualidad\/es-herencia-autosomica-recesiva\"><span style=\"font-weight: 400;\">Rare Commons<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Diagnosis and treatment of diseases hereditary metabolic Pablo Sanjurjo, Antonio Baldellou 4\u00aaEdici\u00f3n<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Angle B, Burton BK. Risk of sudden death and acute events that threaten life in patients with glutaric acidemia type II. Mol Genet Metab. 2008 jan; 93 (1): 36-9. Epub 2007 oct 31.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17977044\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cornelius N, Frerman FE, Corydon TJ, Palmfeldt J, Bross P, Gregersen N, Olsen RK. Molecular mechanisms of the response of riboflavin in patients with variations of ETF-QO and deficiency multiple dehydrogenation of acyl-CoA. Hum Mol Genet. 2012 August 1; 21 (15): 3435-48. doi: 10.1093 \/ hmg \/ dds175. Epub 2012 may 18.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22611163\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Curcoy A, Olsen RK, Ribes A, trench coats V, Vilaseca MA, Campistol J, Osorio JH, Andresen BS, Gregersen N. delayed Form of the deficiency of flavoprotein by transfer of electrons beta. Mol Genet Metab. 2003 apr; 78 (4): 247-9.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12706375\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Goodman SI, Binard RJ, Woontner MR, Frerman FE. Glutaric acidemia type II: structure and gene mutations in the flavoprotein electron transfer: gene ubiquinone oxidoreductase (ETF: QO). Mol Genet Metab. 2002 Sep-Oct; 77 (1-2): 86-90.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12359134\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Olsen RK, Andresen BS, Christensen E, Bross P, Skovby F, Gregersen N. Clear relationship between the genotype and the phenotype of ETF \/ ETFDH in patients with deficiency of dehydrogenation of acyl-CoA multiple. Hum Mutat. 2003 Jul; 22 (1): 12-23.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12815589\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Olsen RK, Olpin SE, Andresen BS, Miedzybrodzka ZH, Pourfarzam M, Merinero B, Frerman FE, Beresford MW, Dean JC, Cornelius N, Andersen O, Oldfors A, Holme E, Gregersen N, Turnbull DM, Morris AA. Mutations in ETFDH as one of the main causes of the deficiency of dehydrogenation of acyl-CoA multiple sensitive to riboflavin. Brain. 2007 Aug; 130 (Pt 8): 2045-54. Epub 2007 June 20.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17584774\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Olsen RK, Pourfarzam M, Morris AA, Dias RC, Knudsen I, Andresen BS, Gregersen N, Olpin SE. Myopathy of lipid storage and respiratory failure by mutations of ETFQO in a patient with deficiency of dehydrogenation of acyl-CoA late-onset. J Inherit Metab Dis. 2004; 27 (5): 671-8.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15669683\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Purevjav E, Kimura M, Takusa And, Ohura T, Tsuchiya M, Hara N, Fukao T, Yamaguchi S. molecular Study of the electron transfer flavoprotein deficiency of the alpha-subunit in two japanese children with different phenotypes of glutaric acidemia type II. Eur J Clin Invest. 2002 Sep; 32 (9): 707-12.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12486872\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Schiff M, Froissart R, Olsen RK, Acquaviva C, Vianey-Saban, C. Deficiency of flavoprotein electronic transfer: functional aspects and molecular. Mol Genet Metab. 2006 Jun; 88 (2): 153-8. Epub 2006 February 28.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16510302\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Takken T, Custers J, Visser G, Dorland L, Helders P, de Koning, T. Evidence of prolonged exercise on two children with a mild deficiency of acyl-CoA-dehydrogenase multiple. Nutr Metab (Lond). 2005 may 20; 2 (1): 12.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15907213\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><span style=\"font-weight: 400;\"> or <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1159171\/\"><span style=\"font-weight: 400;\">free article on PubMed Central<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5874208\/\"><span style=\"font-weight: 400;\">Heterogeneous Phenotypes in Lipid Storage Myopathy Due to <\/span><i><span style=\"font-weight: 400;\">ETFDH<\/span><\/i><span style=\"font-weight: 400;\"> Gene Mutations Corrado Angelini, Daniela Tavian, [...], and Johannes Zschocke\u00a0<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23727839\"><span style=\"font-weight: 400;\">Secondary deficiency of coenzyme Q10 and oxidative stress in cultured fibroblasts of patients with deficiency of dehydrogenation of Acyl-CoA multiple sensitive to riboflavin.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><\/a><span style=\"font-weight: 400;\">Cornelius N , Byron C , Hargreaves I , War, PF , Furdek AK , Land J , Radford WW , Frerman F , Corydon TJ , Gregersen N , Olsen RK .<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23628458\"><span style=\"font-weight: 400;\">Increase of the coenzyme muscle coenzyme Q10 MADD sensitive to riboflavin with gene mutations in ETFDH due to the proliferation mitochondrial secondary. <\/span><\/a><span style=\"font-weight: 400;\">Wen B <\/span><span style=\"font-weight: 400;\">1<\/span><span style=\"font-weight: 400;\"> , Li D , Shan J , Liu S , Li W , Zhao Y , Lin P , Zheng J , Li D , Gong Y , Yan C .<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19249206\"><span style=\"font-weight: 400;\">Mutations in ETFDH, CoQ10 levels and activities of the respiratory chain in patients with deficiency, multiple acyl-CoA dehydrogenase deficiency responsive to riboflavin. Liang WC <\/span><span style=\"font-weight: 400;\">1<\/span><span style=\"font-weight: 400;\"> , Ohkuma A , Hayashi YK , L\u00f3pez LC , Hirano M , Nonaka I , Noguchi S , Chen LH , Jong YJ , Nishino I .<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20937244\"><span style=\"font-weight: 400;\">The flavoprotein electronic transfer: ubiquinone oxidoreductases. <\/span><\/a><span style=\"font-weight: 400;\">Watmough NJ <\/span><span style=\"font-weight: 400;\">1<\/span><span style=\"font-weight: 400;\"> , Frerman FE .<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24522293\"><span style=\"font-weight: 400;\">Deficiency of dehydrogenation of Acyl-CoA multiple sensitive to riboflavin in 13 cases, and a review of the literature in patients from mainland China. <\/span><\/a><span style=\"font-weight: 400;\">Zhu M <\/span><span style=\"font-weight: 400;\">1<\/span><span style=\"font-weight: 400;\"> , Zhu X <\/span><span style=\"font-weight: 400;\">1<\/span><span style=\"font-weight: 400;\"> , Qi X <\/span><span style=\"font-weight: 400;\">2<\/span><span style=\"font-weight: 400;\"> , Weijiang D <\/span><span style=\"font-weight: 400;\">2<\/span><span style=\"font-weight: 400;\"> , Yu And <\/span><span style=\"font-weight: 400;\">1<\/span><span style=\"font-weight: 400;\"> , Wan H , Hong D.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4908180\/pdf\/main.pdf\"><span style=\"font-weight: 400;\">Riboflavin-Responsive and-Non-responsive Mutations in FAD Synthase Cause Multiple Acyl-CoA Dehydrogenase and Combined Respiratory-Chain Deficiency<\/span><\/a><span style=\"font-weight: 400;\"> Rikke K. J. Olsen<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28433476\"><span style=\"font-weight: 400;\">Patient with deficiency disease of dehydrogenation of acyl-CoA and multiple mutations FLAD1 benefits of the therapy with riboflavin.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><\/a><span style=\"font-weight: 400;\">Auranen M<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19265687\"><span style=\"font-weight: 400;\">New gene mutations in ETFDH in chinese patients with deficiency, multiple acyl-CoA dehydrogenase sensitive to riboflavin<\/span><span style=\"font-weight: 400;\"><br \/><\/span><\/a><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Law%20LK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19265687\"><span style=\"font-weight: 400;\">Law LK\u00a0<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12815589\"><span style=\"font-weight: 400;\">Clear relationship between genotype ETF \/ ETFDH and phenotype in patients with deficiency of multiple dehydrogenation of acyl-CoA<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Olsen%20RK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=12815589\"><span style=\"font-weight: 400;\">Olsen RK<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5883299\/pdf\/12920_2018_Article_356.pdf\"><span style=\"font-weight: 400;\">Patient with disease-deficiency of acyl-CoA dehydrogenase deficiency and mutations in ETFDH benefits of therapy with riboflavin: a case report<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Goh%20LL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=29615056\"><span style=\"font-weight: 400;\">Goh LL<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27000805\"><span style=\"font-weight: 400;\">Significant clinical heterogeneity with genotype ETFDH similar in three chinese patients with deficiency, multiple acyl-CoA dehydrogenase deficiency of late-onset Fu HX<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6031868\/pdf\/main.pdf\"><span style=\"font-weight: 400;\">New mutations <\/span><i><span style=\"font-weight: 400;\">ETFDH<\/span><\/i><\/a><span style=\"font-weight: 400;\"> in four cases of deficiency, multiple acyl-CoA dehydrogenase sensitive to riboflavin <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Fan%20X%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=29988809\"><span style=\"font-weight: 400;\">Fan X\u00a0<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/watermark.silverchair.com\/dds175.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAhcwggITBgkqhkiG9w0BBwagggIEMIICAAIBADCCAfkGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMUoVF2ZmJrM5AuYFAAgEQgIIBysDOm7904FGcC2vrNuiMVgwn0tInFY42F9J42d-PJrTzPZghzIr80FP72FBAt_VbqH-xUn5_cIdYAnrgVMlsVBvNATolQP4I5gVy5xczBFctc1zurpBNBISHz5AcDq6Of8kvPYTJWbioReF5n7qMgnq63teG6b9eR_0emxasdqpbu1pAJT1nYuQoqTxmppR4sn7dwMa2n0S93QIUPEZdiHDcb3aIabOlsbfBncgHVjjGErvOCYcCkPzxfPAKU2Rrh9osg714q4wjqtHZ1gVmh7YJm0XQ9DMrRBW69F7e7O-Y8lac0x5trf2cdaocNyQkoJi_z_RW6Kv-3l-WWi0XwNeGxtTkLptOnXYnrxdtki_GpODG9cftgvgxoKd1DO6Zm6APmrZnccrls-vuUUUhe0zIm25-A6YoobHkn2V3O9NSwWhepGs3OoPVeUeK0HFdLEEBDWeFqXZF-pntvA5SbZEpMGDpkqY3Eq-lx4vYv5d5z8ykEjmHa3jsdh5M89n-bTj4Bm20UQ9rrJIr3NLE2FDQNYWGXj1Tq3-z_b-Y6AMEBzfKYQPD-_SdMJyr7Nd8EGid18e2bkfYCyBaqdtlo469MNsDoyDSJfRR\"><span style=\"font-weight: 400;\">Molecular mechanisms of the response to riboflavin in patients with variations of ETF-QO and deficiency multiple dehydrogenation of acyl-CoA <\/span><\/a><span style=\"font-weight: 400;\">\u00a0<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Cornelius%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22611163\"><span style=\"font-weight: 400;\">Cornelius N<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4513616\/pdf\/12883_2015_Article_380.pdf\"><span style=\"font-weight: 400;\">The syndrome of the vertebral column as an initial manifestation of the deficiency of acyl-CoA dehydrogenase of late onset: a case report and a review of the literature<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Peng%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=26205240\"><span style=\"font-weight: 400;\">Peng And<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26821934\"><span style=\"font-weight: 400;\">Sensory neuropathy severe in patients with deficiency, multiple acyl-CoA dehydrogenase start in adults<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Wang%20Z%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=26821934\"><span style=\"font-weight: 400;\">Wang Z<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25556768\"><span style=\"font-weight: 400;\">Myopathy booster for storage of lipids due to the deficiency of acyl-coenzyme a dehydrogenase<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Whitaker%20CH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25556768\"><span style=\"font-weight: 400;\">Whitaker CH<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/50\/21\/50_21_2663\/_pdf\/-char\/en\"><span style=\"font-weight: 400;\">A case of deficiency, multiple acyl-CoA dehydrogenase sensitive to riboflavin late-onset manifested as rhabdomyolysis, recurrent and acute renal failure<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Izumi%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22041377\"><span style=\"font-weight: 400;\">Izumi R<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4222585\/pdf\/s13023-014-0117-5.pdf\"><span style=\"font-weight: 400;\">Clinical and genetic heterogeneity of the deficiency of acyl-coenzyme A dehydrogenase deficiency, multiple late-onset<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Gr%C3%BCnert%20SC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25200064\"><span style=\"font-weight: 400;\">Gr\u00fcnert SC<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22190129\"><span style=\"font-weight: 400;\">Deficiency of acyl-CoA dehydrogenase sensitive to riboflavin with genetic defect unknown<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Cotelli%20MS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22190129\"><span style=\"font-weight: 400;\">Cotelli MS\u00a0<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27000805\"><span style=\"font-weight: 400;\">Significant clinical heterogeneity with genotype ETFDH similar in three chinese patients with deficiency, multiple acyl-CoA dehydrogenase deficiency of late-onset <\/span><\/a><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Fu%20HX%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=27000805\"><span style=\"font-weight: 400;\">Fu HX\u00a0<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17584774\"><span style=\"font-weight: 400;\">Mutations in ETFDH as the main cause of deficiency of dehydrogenation of acyl-CoA multiple sensitive to riboflavin <\/span><\/a><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Olsen%20RK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=17584774\"><span style=\"font-weight: 400;\">Olsen RK\u00a0<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28433476\"><span style=\"font-weight: 400;\">Patient with deficiency disease of dehydrogenation of acyl-CoA and multiple mutations FLAD1 benefits of the therapy with riboflavin<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Auranen%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28433476\"><span style=\"font-weight: 400;\">Auranen M<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22041377\"><span style=\"font-weight: 400;\">A case of deficiency, multiple acyl-CoA dehydrogenase sensitive to riboflavin late-onset manifested as rhabdomyolysis, recurrent, and kidney failure agud<\/span><\/a><span style=\"font-weight: 400;\">to <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Izumi%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22041377\"><span style=\"font-weight: 400;\">Izumi R<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26821934\"><span style=\"font-weight: 400;\">Sensory neuropathy severe in patients with deficiency, multiple acyl-CoA dehydrogenase start in adults<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Wang%20Z%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=26821934\"><span style=\"font-weight: 400;\">Wang Z<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28914566\"><span style=\"font-weight: 400;\">A new mutation in ETFDH in an adult patient with deficiency, multiple acyl-CoA dehydrogenase sensitive to riboflavin late-onset<\/span><span style=\"font-weight: 400;\"><br \/><\/span><\/a><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Chen%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28914566\"><span style=\"font-weight: 400;\">Chen M<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4799539\/pdf\/CMJ-129-142.pdf\"><span style=\"font-weight: 400;\">A cohort study historical on the efficacy of glucocorticoids and riboflavin in patients with deficiency, multiple acyl-CoA dehydrogenase deficiency of late-onset<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Liu%20XY%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=26830983\"><span style=\"font-weight: 400;\">Liu XY<\/span><\/a><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-116ff1a elementor-section-height-min-height elementor-section-boxed elementor-section-height-default elementor-section-items-middle\" data-id=\"116ff1a\" data-element_type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-9770378\" data-id=\"9770378\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-f637c0e elementor-widget elementor-widget-sc-heading\" data-id=\"f637c0e\" data-element_type=\"widget\" data-widget_type=\"sc-heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div id=\"wt-at-f637c0e\" class=\"headng-wrap center\">\r\n\t\t\t<div class=\"section-heading\">\r\n\t\t\t\t\t\t\t<h4\r\n\t\t\t\t \t\t\t\t>How am I supposed to act<\/h4>\r\n\t\t\t\t\t\t\t\t\t\t\t\t<h2\r\n\t\t\t\t \t\t\t\t>Emergency protocol GA Type 1<\/h2>\r\n\t\t\t\t\t\t\t\t\t\t\t\t<p\r\n\t\t\t\t \t\t\t\t>Know which is the emergency protocol for  Glutaric Acidemia type 1 (GAT AGT) <br>and learn how to act.&nbsp;<\/p>\r\n\t\t\t\t\t\t\t<\/div>\r\n\t\t<\/div>\r\n\r\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3955d4b wt-align-center elementor-widget elementor-widget-sc_button\" data-id=\"3955d4b\" data-element_type=\"widget\" data-settings=\"{&quot;btn_style&quot;:&quot;1&quot;}\" data-widget_type=\"sc_button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div id=\"wt-at-3955d4b\" class=\"wt-button-wrap\">\r\n\t\t\t<a href=\"https:\/\/asipagac.com\/wp-content\/uploads\/2025\/03\/protocolo-emergia-ga-1.pdf\" class=\"dl-btn-2\">Get protocol<span><\/span><\/a>\t\t<\/div>\r\n\r\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t<div class=\"elementor-element elementor-element-c077ba5 e-flex e-con-boxed e-con e-parent\" data-id=\"c077ba5\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2d4d14c elementor-widget elementor-widget-menu-anchor\" data-id=\"2d4d14c\" data-element_type=\"widget\" data-widget_type=\"menu-anchor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-menu-anchor\" id=\"sobre-la-condicion-tipo-2\"><\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ed6154e elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"ed6154e\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-c63d3cb\" data-id=\"c63d3cb\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2726d81 elementor-invisible elementor-widget elementor-widget-sc-heading\" data-id=\"2726d81\" data-element_type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInUp&quot;}\" data-widget_type=\"sc-heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div id=\"wt-at-2726d81\" class=\"headng-wrap left\">\r\n\t\t\t<div class=\"section-heading\">\r\n\t\t\t\t\t\t\t<h4\r\n\t\t\t\t \t\t\t\t>GA Type 2<\/h4>\r\n\t\t\t\t\t\t\t\t\t\t\t\t<h2\r\n\t\t\t\t \t\t\t\t>Glutaric Acidemia type 2 <br> (GA2) <\/h2>\r\n\t\t\t\t\t\t\t\t\t\t\t\t<p\r\n\t\t\t\t \t\t\t\t>Glutaric Acidemia type 2 is an inherited disease that prevents the body from\nbreaking down proteins and fats to produce energy.<\/p>\r\n\t\t\t\t\t\t\t<\/div>\r\n\t\t<\/div>\r\n\r\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-0a54031\" data-id=\"0a54031\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-7fc229a tipo-condicion-imagen elementor-widget elementor-widget-sc_video_box\" data-id=\"7fc229a\" data-element_type=\"widget\" data-widget_type=\"sc_video_box.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t        <div class=\"dl-video-box-wrap\">\r\n            <img decoding=\"async\" width=\"825\" height=\"549\" src=\"https:\/\/asipagac.com\/wp-content\/uploads\/2025\/03\/ga-tipo-2-1024x681.jpg\" class=\"attachment-large size-large wp-image-1849\" alt=\"\" srcset=\"https:\/\/asipagac.com\/wp-content\/uploads\/2025\/03\/ga-tipo-2-1024x681.jpg 1024w, https:\/\/asipagac.com\/wp-content\/uploads\/2025\/03\/ga-tipo-2-300x200.jpg 300w, https:\/\/asipagac.com\/wp-content\/uploads\/2025\/03\/ga-tipo-2-768x511.jpg 768w, https:\/\/asipagac.com\/wp-content\/uploads\/2025\/03\/ga-tipo-2.jpg 1500w\" sizes=\"(max-width: 825px) 100vw, 825px\" \/>\t\t\t            <div class=\"dl-video-box-overlay\">\r\n\t\t\t\t\t\t\t\t                <div class=\"dl-video-box-icon\">\r\n                    <a href=\"https:\/\/www.youtube.com\/watch?v=jyscRA5CY68\" class=\"veno-lightbox\" data-overlay=\"\" data-autoplay=\"true\" data-vbtype=\"video\">\r\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"dl-vb-2\">\r\n\t                            <i class=\"fa fa-play\"><\/i>\r\n\t                            <div class=\"ripple\"><\/div>\r\n\t                        <\/div>\r\n\t\t\t\t\t\t                    <\/a>\r\n                <\/div>\r\n\t\t\t\t            <\/div>\r\n\t\t\t        <\/div>\r\n        \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t<div class=\"elementor-element elementor-element-632f1054 e-flex e-con-boxed e-con e-parent\" data-id=\"632f1054\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-26dae32e elementor-widget elementor-widget-n-accordion\" data-id=\"26dae32e\" data-element_type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;all_collapsed&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-6510\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-6510\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Our professionals explain  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-6510\" class=\"elementor-element elementor-element-74c25ac e-con-full e-flex e-con e-child\" data-id=\"74c25ac\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-117ce9a9 elementor-widget elementor-widget-text-editor\" data-id=\"117ce9a9\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">People with GA-2 have defective genes responsible for the transfer of electrons from the respiratory chain of the mitochondria (organelle of the cell that produces energy for your activity).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-6511\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"2\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-6511\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Definition <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-6511\" class=\"elementor-element elementor-element-34906ee4 e-con-full e-flex e-con e-child\" data-id=\"34906ee4\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6374b7b9 elementor-widget elementor-widget-text-editor\" data-id=\"6374b7b9\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>The Argininosuccinic Acidemia type 2 (GTA 2) is a rare genetic disorder that affects the metabolism of fatty acids and certain amino acids, causing a toxic buildup of organic acids in the body. This disease belongs to the Congenital Errors of the Metabolism and is also classified as a aciduria or organic aciduria dicarbox\u00edlica multiple .<\/p><p>The AGT-2 are caused by mutations in the genes encoding the flavoprotein electron transfer (ETF) or ETF-ubiquinone oxidoreductase (ETF-QO) , two enzymes critical for cellular energy metabolism. The deficiency in these enzymes alter the process of oxidation of fatty acids and amino acids, disrupting the production of energy and generating an accumulation of toxic substances, such as long-chain fatty acids and dicarboxylic acids in the blood and tissues.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-6512\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"3\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-6512\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Cause <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-6512\" class=\"elementor-element elementor-element-1c54d7a5 e-con-full e-flex e-con e-child\" data-id=\"1c54d7a5\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6386f31c elementor-widget elementor-widget-text-editor\" data-id=\"6386f31c\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">People with GA-2 have defective genes responsible for the transfer of electrons from the respiratory chain of the mitochondria (organelle of the cell that produces energy for your activity).<\/span><\/p><p><span style=\"font-weight: 400;\">Results from the deficiency or mutations in any of the three genes, <\/span><a href=\"https:\/\/ghr.nlm.nih.gov\/gene\/ETFA\"><span style=\"font-weight: 400;\">ETFA<\/span><\/a><span style=\"font-weight: 400;\"> , <\/span><a href=\"https:\/\/ghr.nlm.nih.gov\/gene\/ETFB\"><span style=\"font-weight: 400;\">ETFB<\/span><\/a><span style=\"font-weight: 400;\"> and <\/span><a href=\"https:\/\/ghr.nlm.nih.gov\/gene\/ETFDH\"><span style=\"font-weight: 400;\">ETFDH<\/span><\/a><span style=\"font-weight: 400;\">:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The genes for the subunits alpha (ETFA: 15q23-q25) of the flavoprotein electron transfer ETF.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The genes for the subunits beta (ETFB: 19q13.3-q13.4) of the flavoprotein electron transfer ETF.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The flavoprotein dehydrogenase electronic transfer - ubiquinone oxidoreductase (ETFDH-QO: 4q32-q35).<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">People with mutations that result in a complete loss of any one of the enzymes, are likely to experience more severe symptoms.<\/span><\/p><p><span style=\"font-weight: 400;\">Mutations that allow the enzyme to retain activity may result in milder forms of the disorder.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-6513\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"4\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-6513\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> What happens  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-6513\" class=\"elementor-element elementor-element-13accd42 e-con-full e-flex e-con e-child\" data-id=\"13accd42\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4494a53f elementor-widget elementor-widget-text-editor\" data-id=\"4494a53f\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">GA 2 causes of the enzymes needed to not function properly or does not occur at all. The function of these enzymes are normally active in the <\/span><a href=\"https:\/\/ghr.nlm.nih.gov\/art\/large\/cellmitochondria.jpeg\"><span style=\"font-weight: 400;\">mitochondria<\/span><\/a><span style=\"font-weight: 400;\"> (the centers of cells producing energy) is to help generate energy for the body, using the decomposition of fats and proteins from the food we eat and the stored in the body.<\/span><\/p><p><span style=\"font-weight: 400;\">These nutrients are only partially degraded, accumulate in the cells and damage them, causing the signs and symptoms of glutaric acidemia type II.<\/span><\/p><p><span style=\"font-weight: 400;\">When you lack one of the enzymes, the body cannot break down protein and fat for energy, and must rely on glucose. In the body there is a limited amount of glucose, and when it has timed out (we don&#039;t eat for a period of time, we forget a meal or sleep), the body is using fat and proteins. Due to this failure, it does not achieve successfully, and leads to the accumulation of <\/span><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/glutaricAcid.html\"><span style=\"font-weight: 400;\">acid glut\u00e1rico<\/span><\/a><span style=\"font-weight: 400;\"> and other harmful substances in the blood. Also causes a low level of sugar in the blood, called <\/span><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/hypoglycemia.html\"><span style=\"font-weight: 400;\">hypoglycemia<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p><p><span style=\"font-weight: 400;\">Typical illnesses of childhood can cause a formation of acid glut\u00e1rico in the body, because the body needs more energy and break down its fat and protein to get it.<\/span><\/p><p><i><span style=\"font-weight: 400;\">Defects in the pathway of the mitochondrial complex ETF\/ETF-QO that transfers electrons from the first stage of the betaoxidaci\u00f3n to the electron transport system, block the beta-oxidation of fatty acids, oxidation of branched-chain amino acids and Glutaril-CoA in the metabolic pathway of lysine, tryptophan and hidrolisina.<\/span><\/i><\/p><p><i><span style=\"font-weight: 400;\">The deficiency of acilcoenzima A dehydrogenase multiple sensitive to riboflavin is characterized, among other features, by a decrease in the ability of beta-oxidation of fatty acids. 3 protein uncoupling in muscle (UCP3; 602044 ) positively regulates in conditions that increase the levels of free fatty acid circulating and \/ or decrease the betaoxidaci\u00f3n of fatty acids. All parameters were restored to control values after treatment with riboflavin. is due to the accumulation of fatty acids in muscle \/ acylCoA.<\/span><\/i><\/p><p><span style=\"font-weight: 400;\">MADD due to mutations in ETFDH may result in myopathy, isolated with secondary deficiency of coenzyme Q10<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-6514\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"5\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-6514\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Prevalence  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-6514\" class=\"elementor-element elementor-element-2dec4878 e-con-full e-flex e-con e-child\" data-id=\"2dec4878\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-cfd7884 elementor-widget elementor-widget-text-editor\" data-id=\"cfd7884\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">Glutaric acidemia type II is a very rare disorder; its precise incidence is unknown. It has been reported in several different ethnic groups. The prevalence at birth is estimated to be 1\/200.000, but there are large variations between countries and ethnic groups.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-6515\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"6\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-6515\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Prognosis  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-6515\" class=\"elementor-element elementor-element-7867e05e e-con-full e-flex e-con e-child\" data-id=\"7867e05e\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6267240a elementor-widget elementor-widget-text-editor\" data-id=\"6267240a\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">There is a protocol of treatment for the neonatal forms of serious, but early diagnosis and the rapid introduction of a dietary treatment (restriction of <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_p#protenas\"><span style=\"font-weight: 400;\">proteins<\/span><\/a><span style=\"font-weight: 400;\"> and <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_g#grasas\"><span style=\"font-weight: 400;\">fat<\/span><\/a><span style=\"font-weight: 400;\">), <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_r#riboflavina\"><span style=\"font-weight: 400;\">riboflavin<\/span><\/a><span style=\"font-weight: 400;\"> (vitamin B2) and <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_c#coenzima_Q10\"><span style=\"font-weight: 400;\">coenzyme Q10<\/span><\/a><span style=\"font-weight: 400;\"> you can improve the prognosis, especially in the forms late and miop\u00e1ticas.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-6516\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"7\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-6516\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Classification  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-6516\" class=\"elementor-element elementor-element-10bf6d94 e-con-full e-flex e-con e-child\" data-id=\"10bf6d94\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2e22dbbe elementor-widget elementor-widget-text-editor\" data-id=\"2e22dbbe\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">The clinical picture of GA II according to the genetic defect is indistinguishable; as each defect can lead to mild or severe.<\/span><\/p><p><span style=\"font-weight: 400;\">According to the clinical features are divided into:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neonatal onset: usually very serious, are characterized by hypoglycemia is not ketotic serious (the descent of the <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_g#glucosa\"><span style=\"font-weight: 400;\">glucose<\/span><\/a><span style=\"font-weight: 400;\"> in the blood without <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_c#cuerpos_cetnicos\"><span style=\"font-weight: 400;\">ketone bodies<\/span><\/a><span style=\"font-weight: 400;\">), <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_a#acidosis\"><span style=\"font-weight: 400;\">acidosis<\/span><\/a><span style=\"font-weight: 400;\"> metabolic <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_a#afectacin_multisistmica\"><span style=\"font-weight: 400;\">involvement multisystem<\/span><\/a><span style=\"font-weight: 400;\"> and excretion of large amounts of <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_m#metabolitos\"><span style=\"font-weight: 400;\">metabolites<\/span><\/a><span style=\"font-weight: 400;\"> derivatives of fatty acids and amino acids.<\/span><ul><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">TYPE I: with congenital anomalies (such as the <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_d#dismorfia\"><span style=\"font-weight: 400;\">dysmorphia<\/span><\/a><span style=\"font-weight: 400;\"> facial, indicating that the effect is already prenatal).<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">TYPE II: without congenital anomalies.<\/span><\/li><\/ul><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Late-onset type III. The symptoms and the age of presentation are highly variable (juvenile, adult) and is characterized by recurrent episodes of <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_l#letargia\"><span style=\"font-weight: 400;\">lethargy<\/span><\/a><span style=\"font-weight: 400;\">, vomiting, hypoglycemia, metabolic acidosis, and <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_h#hepatomegalia\"><span style=\"font-weight: 400;\">hepatomegaly <\/span><\/a><span style=\"font-weight: 400;\">often preceded by metabolic stress and by a <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_d#descompensacin_metablica\"><span style=\"font-weight: 400;\">metabolic decompensation<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Myopathic Type , of late presentation sometimes in adulthood, which causes muscle pain, weakness, exercise intolerance, and myopathy (muscle injury) by deposit of <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_l#lpidos\"><span style=\"font-weight: 400;\">lipids<\/span><\/a><span style=\"font-weight: 400;\">. It is often intermittent and is only evident in periods of disease or catabolic stress.<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">It is important to note that it has been shown that treatment with riboflavin improves symptoms and metabolic profiles in many patients, particularly those with type III, the late onset and milder form.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-6517\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"8\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-6517\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Symptoms  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-6517\" class=\"elementor-element elementor-element-59995d42 e-con-full e-flex e-con e-child\" data-id=\"59995d42\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-72422ac7 elementor-widget elementor-widget-text-editor\" data-id=\"72422ac7\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">The symptoms of GA-2 may be very different from person to person. May appear in the period of the newborn or late in childhood, youth and adulthood.<\/span><\/p><p><span style=\"font-weight: 400;\">Some babies have their first symptoms shortly after birth.<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Rapid breathing<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Hypotonia<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Metabolic crisis<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Smell feet &#034;sweaty&#034;<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Heart problems, and liver problems.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Congenital malformations<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Comma<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">If the symptoms occur late, can start at any time from early childhood to adulthood.<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Intermittent States (cyclic vomiting)<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Nausea<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Vomiting<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Muscle weakness, hypotonia<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Periods of hypoglycemia (weak, shaky or dizzy with cold, clammy skin)<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Metabolic crisis<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">Hypoglycemia and metabolic crisis may occur:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">After exercise<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">After intake of high amount of protein<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A lot of time in fasting<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">During illness or infection<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Deficit <\/span><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/l_carnitine.html\"><span style=\"font-weight: 400;\">carnitine<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Involuntary movements<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">Some people with GA-2 never have any symptoms, and only affected after they are diagnosed with a brother or sister.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-6518\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"9\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-6518\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Treatments  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-6518\" class=\"elementor-element elementor-element-c0357e8 e-con-full e-flex e-con e-child\" data-id=\"c0357e8\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-97eea66 elementor-widget elementor-widget-text-editor\" data-id=\"97eea66\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">A small number of newborns with the neonatal type have shown positive effects to the treatment.<\/span><\/p><p><span style=\"font-weight: 400;\">In the late onset type with prompt treatment and care, children and adults with GA-2 generally live healthy lives with a normal growth and development.<\/span><\/p><p><span style=\"font-weight: 400;\">The goal of treatment is to prevent long-term problems. However, children who have metabolic crisis metabolic may develop learning problems for life.<\/span><\/p><p><span style=\"font-weight: 400;\">The treatment is usually needed during the entire life, it is usually individualized, adapted to the characteristics and needs of each child.<\/span><\/p><ol><li><span style=\"font-weight: 400;\"> Avoid going too long without eating: they need to eat frequently to prevent hypoglycemia or a metabolic crisis.  Your doctor will tell you how often you need to feed your child. It is important that infants be fed during the night. It is possible that you need to wake them up to eat if they do not wake up alone. Metabolic specialists will provide you with a protocol of appropriate nourishment  for the baby. Your doctor will also explain the \"emergency regimen\" during illness or other occasions that your child does not eat.<\/span><\/li><\/ol><p><span style=\"font-weight: 400;\">Your metabolic expert should continue advising you on the frequency with which your child should eat as it grows.<\/span><\/p><ol start=\"2\"><li><span style=\"font-weight: 400;\"> Diet<\/span><span style=\"font-weight: 400;\"><br \/><\/span><span style=\"font-weight: 400;\">Usually a low fat diet is recommended , low in protein and high in <\/span><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/carbohydrate.html\"><span style=\"font-weight: 400;\">carbohydrates<\/span><\/a><span style=\"font-weight: 400;\"> that<\/span><span style=\"font-weight: 400;\"> give the body the sugar to get the energy they need (bread, cereal, pasta, fruit, vegetables). You should not remove all the fat and protein of the diet, as is needed for the growth and development. But as we've said before, the treatment, including diet, should be adapted to the individual characteristics.<\/span><\/li><\/ol><p><span style=\"font-weight: 400;\">The specialists will create a diet that meets the needs of your child.<\/span><\/p><p><span style=\"font-weight: 400;\">3 - Riboflavin: it is associated with clinical improvement. This is a type of B vitamin (vitamin B2). It helps to convert carbohydrates, proteins and fats into energy for the body.<\/span><\/p><p><span style=\"font-weight: 400;\">4 - Carnitine-helps the body to generate energy from fat in the food and fat stored in the body. It also helps to rid cells of waste harmful produced during the decomposition of fat. Supplements of carnitine can be used as a treatment for some metabolic disorders.<\/span><\/p><ol start=\"5\"><li><span style=\"font-weight: 400;\"> Call your doctor at the beginning of any disease.<\/span><\/li><\/ol><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Poor appetite<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Low energy or extreme drowsiness<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Vomiting<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Diarrhea<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Infection<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Fever<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">During an illness or infection, children with GA-2 have a much higher chance of developing hypoglycemia or a crisis metabolic. Need to drink liquids and eat carbohydrates extra when they are sick, even if they are not hungry, or they may have a crisis metabolic.<\/span><\/p><p><span style=\"font-weight: 400;\">Children who are sick often don&#039;t want to eat. If they can&#039;t eat, or if they show signs of hypoglycaemia or a crisis metabolic, they may need to be treated in the hospital. Ask your doctor about the metabolic whether you should carry a special letter to travel with medical instructions for the care of your child.<\/span><\/p><p><span style=\"font-weight: 400;\">The treatment of the more severe phenotypes consists in the restriction of fats and proteins and the adoption of a diet rich in carbohydrates. It is essential to strictly avoid fasting and other types of attacks precipitant. You must have regimes of urgency to any decompensation, metabolic.<\/span><\/p><p><span style=\"font-weight: 400;\">It is also observed a positive effect of supplementation with Coenzyme Q10.\u00a0\u00a0<\/span><\/p><p><span style=\"font-weight: 400;\">For cases of moderately severe has used 3-hydroxybutyrate with success, but further studies will be necessary in this regard.<\/span><\/p><p><span style=\"font-weight: 400;\">Do not use any supplement without consulting your specialist.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-6519\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"10\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-6519\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Complications  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-6519\" class=\"elementor-element elementor-element-5653b751 e-con-full e-flex e-con e-child\" data-id=\"5653b751\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4d8656d9 elementor-widget elementor-widget-text-editor\" data-id=\"4d8656d9\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">Can cause <\/span><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/metabolicCrisis.html\"><span style=\"font-weight: 400;\">crisis metabolic<\/span><\/a><span style=\"font-weight: 400;\">. Some of the first symptoms of a crisis metabolic are:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Extreme drowsiness<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Behavior changes<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Irritable mood<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Muscle weakness<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Poor appetite<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">Other symptoms are followed:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Fever<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Nausea<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Diarrhea<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Vomiting<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Hypoglycemia<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Increased levels of acidic substances in the blood, called <\/span><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/metabolicAcidosis.html\"><span style=\"font-weight: 400;\">metabolic acidosis<\/span><\/a><\/li><\/ul><p><span style=\"font-weight: 400;\">If this is not a crisis metabolic, a child with a GA-2 can develop:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Breathing problems<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/seizures.html\"><span style=\"font-weight: 400;\">Seizures<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/coma.html\"><span style=\"font-weight: 400;\">Comma<\/span><\/a><span style=\"font-weight: 400;\">sometimes leads to the death<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">GA2 may cause <\/span><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/metabolicCrisis.html\"><span style=\"font-weight: 400;\">crisis metabolic<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p><p><span style=\"font-weight: 400;\">Some of the first symptoms of a crisis metabolic are:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Extreme drowsiness<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Behavior changes<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Irritable mood<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Muscle weakness<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Poor appetite<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Fever<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Nausea<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Diarrhea<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Vomiting<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Hypoglycemia<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Increased levels of acidic substances in the blood, called <\/span><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/metabolicAcidosis.html\"><span style=\"font-weight: 400;\">metabolic acidosis<\/span><\/a><\/li><\/ul><p><span style=\"font-weight: 400;\">If this is not a crisis metabolic, a child with a GA-2 can develop:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Breathing problems<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/seizures.html\"><span style=\"font-weight: 400;\">Seizures<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/coma.html\"><span style=\"font-weight: 400;\">Comma<\/span><\/a><span style=\"font-weight: 400;\">sometimes leads to the death<\/span><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-65110\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"11\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-65110\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Diagnosis  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-65110\" class=\"elementor-element elementor-element-6d49fb3e e-con-full e-flex e-con e-child\" data-id=\"6d49fb3e\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-73559f96 elementor-widget elementor-widget-text-editor\" data-id=\"73559f96\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><b>PRE-SYMPTOMATIC DIAGNOSIS: <\/b><span style=\"font-weight: 400;\">The newborn screening or testing of the heel for help at the start of adequate treatment, which prevents many of the irregularities and its potential sequelae. It is available in several european countries, but still there is not enough experience in spite of this, due to the low number of cases.The study of the <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_m#mutaciones\"><span style=\"font-weight: 400;\">mutations<\/span><\/a><span style=\"font-weight: 400;\"> in the genes coding for the \u03b1 and \u03b2 subunits of the <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_g#gen\"><span style=\"font-weight: 400;\">gene<\/span><\/a> <i><span style=\"font-weight: 400;\">ETFA\/ETFB <\/span><\/i><span style=\"font-weight: 400;\">and<\/span><i><span style=\"font-weight: 400;\"> ETF-QO <\/span><\/i><span style=\"font-weight: 400;\">confirms the diagnosis.The GA-2 can be confirmed by tests carried out on samples of blood, urine, or skin.\u2013 <\/span><i><span style=\"font-weight: 400;\">In the blood is observed an increase of acylcarnitines of C4-C18, can present a severe decrease of carnitine.\u2013 Usually the analysis of organic acids in urine reveals increments of combinations of dicarboxylic acids, acid glut\u00e1rico, acid etilmal\u00f3nico, 2-hidroxiglutarato and glycine.\u2013 The flow-oxidative fatty acids in fibroblasts (puncture of the skin) and the analysis of acylcarnitine in fibroblasts after incubation with palmitic acid tend to be anomalous.<\/span><\/i><span style=\"font-weight: 400;\">DIAGNOSIS of SYMPTOMATIC: it is performed on the basis of clinical presentation: the concentration of glucose in the blood is low, with absence of <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_c#cuerpos_cetnicos\"><span style=\"font-weight: 400;\">ketone bodies<\/span><\/a><span style=\"font-weight: 400;\">, <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_a#acidosis_lctica\"><span style=\"font-weight: 400;\">lactic acidosis<\/span><\/a><span style=\"font-weight: 400;\"> and a deficiency of <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_c#carnitina\"><span style=\"font-weight: 400;\">carnitine<\/span><\/a><span style=\"font-weight: 400;\">, increase in times of liver enzymes and creatin kinase. In the late is observed in the <\/span><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/glosario\/letter_d#descompensacin_metablica\"><span style=\"font-weight: 400;\">decompensation metabolic<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p><p><span style=\"font-weight: 400;\">PRENATAL DIAGNOSIS: it Is possible to make a prenatal diagnosis when we have identified two pathogenic mutations in the family.<\/span><\/p><p><b>DIFFERENTIAL DIAGNOSIS:<\/b><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Polycystic kidney disease, autosomal recessive<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Carnitine deficiency palmito\u00edl-transferase II<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Syndrome of Zellweger<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Alterations in the biosynthesis of sterols<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">GENETIC counseling: Is inherited as a autosomal recessive, and there is the possibility of genetic counselling.<\/span><\/p><p><span style=\"font-weight: 400;\">If you have found both genetic changes in your child, you may perform DNA testing during future pregnancies. The sample needed for this test is obtained by chorionic villus sampling or <\/span><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/amniocentesis.html\"><span style=\"font-weight: 400;\">amniocentesis<\/span><\/a><span style=\"font-weight: 400;\"> .<\/span><\/p><p><span style=\"font-weight: 400;\">If the DNA tests are not useful, they may perform a test of enzymes in the cells of the fetus. The sample needed for this test is obtained by amniocentesis.<\/span><\/p><p><span style=\"font-weight: 400;\">Parents can choose to be tested during pregnancy or wait until the birth to the baby to be examined. A specialist in genetics can explain your options and to answer questions about prenatal testing or the testing of your baby after birth<\/span><b>.<\/b><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-65111\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"12\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-65111\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> How it is inherited  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-65111\" class=\"elementor-element elementor-element-ac05dbf e-con-full e-flex e-con e-child\" data-id=\"ac05dbf\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4e1d50f elementor-widget elementor-widget-text-editor\" data-id=\"4e1d50f\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">GA-2 is inherited in an <\/span><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/autosomalRecessive.html\"><span style=\"font-weight: 400;\">autosomal recessive.<\/span><\/a><\/p><p><span style=\"font-weight: 400;\">We all have a pair of genes that produce the enzyme ETF and another pair that produces the enzyme ETF: QO.<\/span><\/p><p><span style=\"font-weight: 400;\">In children with GA-2, the gene pair for one of these enzymes is not working properly. These children inherit one non-working gene for the condition from each parent.<\/span><\/p><p><span style=\"font-weight: 400;\">A person must inherit two copies mutated in the same gene (one copy of the mutation from each parent) to develop the disease. If a person inherits a mutated copy of a gene and one normal, in most cases it will be a healthy person, carrier, because, the normal copy is going to compensate for the mutated. Be a person, a carrier means that you do not have the disease, but that has a mutated copy of the gene of the pair of genes.<\/span><\/p><p><span style=\"font-weight: 400;\">Parents of children with GA-2 usually do not have the disorder; but each parent has a single gene is not functional for GA-2, are <\/span><a href=\"http:\/\/www.newbornscreening.info\/GlossaryTerms\/carrier.html\"><span style=\"font-weight: 400;\">carriers<\/span><\/a><span style=\"font-weight: 400;\"> . Carriers do not have a deficiency of GA-2 because the other gene of this pair is working correctly.<\/span><\/p><p><span style=\"font-weight: 400;\">If both parents are carriers of the same mutation of the gene, it can pass on the mutated gene or the normal to their offspring, and this is going to happen at random. If both parents are carriers of the same mutation of the gene can pass on the mutated gene or the normal to their children and this is going to happen at random.<\/span><\/p><p><b>Each one of the children of parents are carriers of the same mutation gene have a 25% chance (1 of 4 possibilities) of inheriting the mutation from both parents and developing the disease.<\/b><span style=\"font-weight: 400;\"> This also means that there is a 75% chance (3 out of 4 possibilities) that the child is not affected by the disease. <\/span><b>This probability remains the same in every pregnancy and in children or girls.<\/b><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">In addition, there is a 25% chance (2 out of 4 possibilities) that the child will inherit one copy of the mutated gene from one of their parents, so they will be healthy but the bearer such as their parents.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Finally, there is a 25% chance (1 of 4 possibilities) that the child inherits both copies of the normal gene. In this case the child will not be suffering the disease, or be a carrier.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">These possible outcomes happen at random. The probability remains the same in every pregnancy and between boys and girls.<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">The brothers and sisters of a baby with a GA-2 have the potential to be carriers or have the disease, even if they have not shown symptoms. It is important to detect because early treatment can prevent serious health problems.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-65112\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"13\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-65112\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Protocols and guidelines  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-65112\" class=\"elementor-element elementor-element-678516cc e-con-full e-flex e-con e-child\" data-id=\"678516cc\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-44040dec elementor-widget elementor-widget-text-editor\" data-id=\"44040dec\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>\u00a0Treatment standard MAD<\/strong><\/p><p>LINK: <a href=\"https:\/\/www.familiasga.com\/wp-content\/uploads\/2018\/10\/TRATAMIENTO-ESTANDAR-MAD.pdf\">https:\/\/www.familiasga.com\/wp-content\/uploads\/2018\/10\/TRATAMIENTO-ESTANDAR-MAD.pdf<\/a><\/p><p><strong>Treatment of decompensation MAD<\/strong><\/p><p>LINK:<\/p><p><a href=\"https:\/\/www.familiasga.com\/wp-content\/uploads\/2018\/10\/TRATAMIENTO-EN-DESCOMPENSACI%C3%93N-MAD.pdf\">https:\/\/www.familiasga.com\/wp-content\/uploads\/2018\/10\/TRATAMIENTO-EN-DESCOMPENSACI%C3%93N-MAD.pdf<\/a><\/p><p><strong>Protocol GA2 2008 BIMDG<\/strong><\/p><p>LINK:<\/p><p><a href=\"https:\/\/www.familiasga.com\/wp-content\/uploads\/2018\/11\/PROTOCOLO-GA2-2008-BIMDG.pdf\">https:\/\/www.familiasga.com\/wp-content\/uploads\/2018\/11\/PROTOCOLO-GA2-2008-<b>BIMDG.pdf<\/b><\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-65113\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"14\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-65113\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Bibliography  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-65113\" class=\"elementor-element elementor-element-7dad95f1 e-con-full e-flex e-con e-child\" data-id=\"7dad95f1\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-68fcdf43 elementor-widget elementor-widget-text-editor\" data-id=\"68fcdf43\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.omim.org\/entry\/231680\"><span style=\"font-weight: 400;\">OMIM<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"http:\/\/evm.health2media.com\/#\/detail-view\/disorder\/2\/101\"><span style=\"font-weight: 400;\">VADEMECUM METABOLICUM<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.rarecommons.org\/es\"><span style=\"font-weight: 400;\">RARE COMMONS<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.newbornscreening.info\/spanish\/parent\/Organic_acid\/GA2.html\"><span style=\"font-weight: 400;\">NEWBORNSCREENING INFO<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/ghr.nlm.nih.gov\/condition\/glutaric-acidemia-type-ii#definition\"><span style=\"font-weight: 400;\">NIH<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/metabolicas.sjdhospitalbarcelona.org\/sites\/default\/files\/deficiencia_mad_es.pdf\"><span style=\"font-weight: 400;\">Guide Metabolic<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.rarecommons.org\/es\/actualidad\/es-herencia-autosomica-recesiva\"><span style=\"font-weight: 400;\">Rare Commons<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Diagnosis and treatment of diseases hereditary metabolic Pablo Sanjurjo, Antonio Baldellou 4\u00aaEdici\u00f3n<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Angle B, Burton BK. Risk of sudden death and acute events that threaten life in patients with glutaric acidemia type II. Mol Genet Metab. 2008 jan; 93 (1): 36-9. Epub 2007 oct 31.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17977044\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cornelius N, Frerman FE, Corydon TJ, Palmfeldt J, Bross P, Gregersen N, Olsen RK. Molecular mechanisms of the response of riboflavin in patients with variations of ETF-QO and deficiency multiple dehydrogenation of acyl-CoA. Hum Mol Genet. 2012 August 1; 21 (15): 3435-48. doi: 10.1093 \/ hmg \/ dds175. Epub 2012 may 18.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22611163\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Curcoy A, Olsen RK, Ribes A, trench coats V, Vilaseca MA, Campistol J, Osorio JH, Andresen BS, Gregersen N. delayed Form of the deficiency of flavoprotein by transfer of electrons beta. Mol Genet Metab. 2003 apr; 78 (4): 247-9.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12706375\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Goodman SI, Binard RJ, Woontner MR, Frerman FE. Glutaric acidemia type II: structure and gene mutations in the flavoprotein electron transfer: gene ubiquinone oxidoreductase (ETF: QO). Mol Genet Metab. 2002 Sep-Oct; 77 (1-2): 86-90.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12359134\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Olsen RK, Andresen BS, Christensen E, Bross P, Skovby F, Gregersen N. Clear relationship between the genotype and the phenotype of ETF \/ ETFDH in patients with deficiency of dehydrogenation of acyl-CoA multiple. Hum Mutat. 2003 Jul; 22 (1): 12-23.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12815589\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Olsen RK, Olpin SE, Andresen BS, Miedzybrodzka ZH, Pourfarzam M, Merinero B, Frerman FE, Beresford MW, Dean JC, Cornelius N, Andersen O, Oldfors A, Holme E, Gregersen N, Turnbull DM, Morris AA. Mutations in ETFDH as one of the main causes of the deficiency of dehydrogenation of acyl-CoA multiple sensitive to riboflavin. Brain. 2007 Aug; 130 (Pt 8): 2045-54. Epub 2007 June 20.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17584774\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Olsen RK, Pourfarzam M, Morris AA, Dias RC, Knudsen I, Andresen BS, Gregersen N, Olpin SE. Myopathy of lipid storage and respiratory failure by mutations of ETFQO in a patient with deficiency of dehydrogenation of acyl-CoA late-onset. J Inherit Metab Dis. 2004; 27 (5): 671-8.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15669683\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Purevjav E, Kimura M, Takusa And, Ohura T, Tsuchiya M, Hara N, Fukao T, Yamaguchi S. molecular Study of the electron transfer flavoprotein deficiency of the alpha-subunit in two japanese children with different phenotypes of glutaric acidemia type II. Eur J Clin Invest. 2002 Sep; 32 (9): 707-12.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12486872\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Schiff M, Froissart R, Olsen RK, Acquaviva C, Vianey-Saban, C. Deficiency of flavoprotein electronic transfer: functional aspects and molecular. Mol Genet Metab. 2006 Jun; 88 (2): 153-8. Epub 2006 February 28.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16510302\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Takken T, Custers J, Visser G, Dorland L, Helders P, de Koning, T. Evidence of prolonged exercise on two children with a mild deficiency of acyl-CoA-dehydrogenase multiple. Nutr Metab (Lond). 2005 may 20; 2 (1): 12.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15907213\"><span style=\"font-weight: 400;\">Citation in PubMed<\/span><\/a><span style=\"font-weight: 400;\"> or <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1159171\/\"><span style=\"font-weight: 400;\">free article on PubMed Central<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5874208\/\"><span style=\"font-weight: 400;\">Heterogeneous Phenotypes in Lipid Storage Myopathy Due to <\/span><i><span style=\"font-weight: 400;\">ETFDH<\/span><\/i><span style=\"font-weight: 400;\"> Gene Mutations Corrado Angelini, Daniela Tavian, [...], and Johannes Zschocke\u00a0<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23727839\"><span style=\"font-weight: 400;\">Secondary deficiency of coenzyme Q10 and oxidative stress in cultured fibroblasts of patients with deficiency of dehydrogenation of Acyl-CoA multiple sensitive to riboflavin.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><\/a><span style=\"font-weight: 400;\">Cornelius N , Byron C , Hargreaves I , War, PF , Furdek AK , Land J , Radford WW , Frerman F , Corydon TJ , Gregersen N , Olsen RK .<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23628458\"><span style=\"font-weight: 400;\">Increase of the coenzyme muscle coenzyme Q10 MADD sensitive to riboflavin with gene mutations in ETFDH due to the proliferation mitochondrial secondary. <\/span><\/a><span style=\"font-weight: 400;\">Wen B <\/span><span style=\"font-weight: 400;\">1<\/span><span style=\"font-weight: 400;\"> , Li D , Shan J , Liu S , Li W , Zhao Y , Lin P , Zheng J , Li D , Gong Y , Yan C .<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19249206\"><span style=\"font-weight: 400;\">Mutations in ETFDH, CoQ10 levels and activities of the respiratory chain in patients with deficiency, multiple acyl-CoA dehydrogenase deficiency responsive to riboflavin. Liang WC <\/span><span style=\"font-weight: 400;\">1<\/span><span style=\"font-weight: 400;\"> , Ohkuma A , Hayashi YK , L\u00f3pez LC , Hirano M , Nonaka I , Noguchi S , Chen LH , Jong YJ , Nishino I .<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20937244\"><span style=\"font-weight: 400;\">The flavoprotein electronic transfer: ubiquinone oxidoreductases. <\/span><\/a><span style=\"font-weight: 400;\">Watmough NJ <\/span><span style=\"font-weight: 400;\">1<\/span><span style=\"font-weight: 400;\"> , Frerman FE .<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24522293\"><span style=\"font-weight: 400;\">Deficiency of dehydrogenation of Acyl-CoA multiple sensitive to riboflavin in 13 cases, and a review of the literature in patients from mainland China. <\/span><\/a><span style=\"font-weight: 400;\">Zhu M <\/span><span style=\"font-weight: 400;\">1<\/span><span style=\"font-weight: 400;\"> , Zhu X <\/span><span style=\"font-weight: 400;\">1<\/span><span style=\"font-weight: 400;\"> , Qi X <\/span><span style=\"font-weight: 400;\">2<\/span><span style=\"font-weight: 400;\"> , Weijiang D <\/span><span style=\"font-weight: 400;\">2<\/span><span style=\"font-weight: 400;\"> , Yu And <\/span><span style=\"font-weight: 400;\">1<\/span><span style=\"font-weight: 400;\"> , Wan H , Hong D.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4908180\/pdf\/main.pdf\"><span style=\"font-weight: 400;\">Riboflavin-Responsive and-Non-responsive Mutations in FAD Synthase Cause Multiple Acyl-CoA Dehydrogenase and Combined Respiratory-Chain Deficiency<\/span><\/a><span style=\"font-weight: 400;\"> Rikke K. J. Olsen<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28433476\"><span style=\"font-weight: 400;\">Patient with deficiency disease of dehydrogenation of acyl-CoA and multiple mutations FLAD1 benefits of the therapy with riboflavin.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><\/a><span style=\"font-weight: 400;\">Auranen M<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19265687\"><span style=\"font-weight: 400;\">New gene mutations in ETFDH in chinese patients with deficiency, multiple acyl-CoA dehydrogenase sensitive to riboflavin<\/span><span style=\"font-weight: 400;\"><br \/><\/span><\/a><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Law%20LK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19265687\"><span style=\"font-weight: 400;\">Law LK\u00a0<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12815589\"><span style=\"font-weight: 400;\">Clear relationship between genotype ETF \/ ETFDH and phenotype in patients with deficiency of multiple dehydrogenation of acyl-CoA<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Olsen%20RK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=12815589\"><span style=\"font-weight: 400;\">Olsen RK<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5883299\/pdf\/12920_2018_Article_356.pdf\"><span style=\"font-weight: 400;\">Patient with disease-deficiency of acyl-CoA dehydrogenase deficiency and mutations in ETFDH benefits of therapy with riboflavin: a case report<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Goh%20LL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=29615056\"><span style=\"font-weight: 400;\">Goh LL<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27000805\"><span style=\"font-weight: 400;\">Significant clinical heterogeneity with genotype ETFDH similar in three chinese patients with deficiency, multiple acyl-CoA dehydrogenase deficiency of late-onset Fu HX<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6031868\/pdf\/main.pdf\"><span style=\"font-weight: 400;\">New mutations <\/span><i><span style=\"font-weight: 400;\">ETFDH<\/span><\/i><\/a><span style=\"font-weight: 400;\"> in four cases of deficiency, multiple acyl-CoA dehydrogenase sensitive to riboflavin <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Fan%20X%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=29988809\"><span style=\"font-weight: 400;\">Fan X\u00a0<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/watermark.silverchair.com\/dds175.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAhcwggITBgkqhkiG9w0BBwagggIEMIICAAIBADCCAfkGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMUoVF2ZmJrM5AuYFAAgEQgIIBysDOm7904FGcC2vrNuiMVgwn0tInFY42F9J42d-PJrTzPZghzIr80FP72FBAt_VbqH-xUn5_cIdYAnrgVMlsVBvNATolQP4I5gVy5xczBFctc1zurpBNBISHz5AcDq6Of8kvPYTJWbioReF5n7qMgnq63teG6b9eR_0emxasdqpbu1pAJT1nYuQoqTxmppR4sn7dwMa2n0S93QIUPEZdiHDcb3aIabOlsbfBncgHVjjGErvOCYcCkPzxfPAKU2Rrh9osg714q4wjqtHZ1gVmh7YJm0XQ9DMrRBW69F7e7O-Y8lac0x5trf2cdaocNyQkoJi_z_RW6Kv-3l-WWi0XwNeGxtTkLptOnXYnrxdtki_GpODG9cftgvgxoKd1DO6Zm6APmrZnccrls-vuUUUhe0zIm25-A6YoobHkn2V3O9NSwWhepGs3OoPVeUeK0HFdLEEBDWeFqXZF-pntvA5SbZEpMGDpkqY3Eq-lx4vYv5d5z8ykEjmHa3jsdh5M89n-bTj4Bm20UQ9rrJIr3NLE2FDQNYWGXj1Tq3-z_b-Y6AMEBzfKYQPD-_SdMJyr7Nd8EGid18e2bkfYCyBaqdtlo469MNsDoyDSJfRR\"><span style=\"font-weight: 400;\">Molecular mechanisms of the response to riboflavin in patients with variations of ETF-QO and deficiency multiple dehydrogenation of acyl-CoA <\/span><\/a><span style=\"font-weight: 400;\">\u00a0<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Cornelius%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22611163\"><span style=\"font-weight: 400;\">Cornelius N<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4513616\/pdf\/12883_2015_Article_380.pdf\"><span style=\"font-weight: 400;\">The syndrome of the vertebral column as an initial manifestation of the deficiency of acyl-CoA dehydrogenase of late onset: a case report and a review of the literature<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Peng%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=26205240\"><span style=\"font-weight: 400;\">Peng And<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26821934\"><span style=\"font-weight: 400;\">Sensory neuropathy severe in patients with deficiency, multiple acyl-CoA dehydrogenase start in adults<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Wang%20Z%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=26821934\"><span style=\"font-weight: 400;\">Wang Z<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25556768\"><span style=\"font-weight: 400;\">Myopathy booster for storage of lipids due to the deficiency of acyl-coenzyme a dehydrogenase<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Whitaker%20CH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25556768\"><span style=\"font-weight: 400;\">Whitaker CH<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/50\/21\/50_21_2663\/_pdf\/-char\/en\"><span style=\"font-weight: 400;\">A case of deficiency, multiple acyl-CoA dehydrogenase sensitive to riboflavin late-onset manifested as rhabdomyolysis, recurrent and acute renal failure<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Izumi%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22041377\"><span style=\"font-weight: 400;\">Izumi R<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4222585\/pdf\/s13023-014-0117-5.pdf\"><span style=\"font-weight: 400;\">Clinical and genetic heterogeneity of the deficiency of acyl-coenzyme A dehydrogenase deficiency, multiple late-onset<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Gr%C3%BCnert%20SC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25200064\"><span style=\"font-weight: 400;\">Gr\u00fcnert SC<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22190129\"><span style=\"font-weight: 400;\">Deficiency of acyl-CoA dehydrogenase sensitive to riboflavin with genetic defect unknown<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Cotelli%20MS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22190129\"><span style=\"font-weight: 400;\">Cotelli MS\u00a0<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27000805\"><span style=\"font-weight: 400;\">Significant clinical heterogeneity with genotype ETFDH similar in three chinese patients with deficiency, multiple acyl-CoA dehydrogenase deficiency of late-onset <\/span><\/a><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Fu%20HX%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=27000805\"><span style=\"font-weight: 400;\">Fu HX\u00a0<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17584774\"><span style=\"font-weight: 400;\">Mutations in ETFDH as the main cause of deficiency of dehydrogenation of acyl-CoA multiple sensitive to riboflavin <\/span><\/a><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Olsen%20RK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=17584774\"><span style=\"font-weight: 400;\">Olsen RK\u00a0<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28433476\"><span style=\"font-weight: 400;\">Patient with deficiency disease of dehydrogenation of acyl-CoA and multiple mutations FLAD1 benefits of the therapy with riboflavin<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Auranen%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28433476\"><span style=\"font-weight: 400;\">Auranen M<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22041377\"><span style=\"font-weight: 400;\">A case of deficiency, multiple acyl-CoA dehydrogenase sensitive to riboflavin late-onset manifested as rhabdomyolysis, recurrent, and kidney failure agud<\/span><\/a><span style=\"font-weight: 400;\">to <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Izumi%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22041377\"><span style=\"font-weight: 400;\">Izumi R<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26821934\"><span style=\"font-weight: 400;\">Sensory neuropathy severe in patients with deficiency, multiple acyl-CoA dehydrogenase start in adults<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Wang%20Z%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=26821934\"><span style=\"font-weight: 400;\">Wang Z<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28914566\"><span style=\"font-weight: 400;\">A new mutation in ETFDH in an adult patient with deficiency, multiple acyl-CoA dehydrogenase sensitive to riboflavin late-onset<\/span><span style=\"font-weight: 400;\"><br \/><\/span><\/a><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Chen%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28914566\"><span style=\"font-weight: 400;\">Chen M<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4799539\/pdf\/CMJ-129-142.pdf\"><span style=\"font-weight: 400;\">A cohort study historical on the efficacy of glucocorticoids and riboflavin in patients with deficiency, multiple acyl-CoA dehydrogenase deficiency of late-onset<\/span><\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Liu%20XY%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=26830983\"><span style=\"font-weight: 400;\">Liu XY<\/span><\/a><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-5ad8bd9 elementor-section-height-min-height elementor-section-boxed elementor-section-height-default elementor-section-items-middle\" data-id=\"5ad8bd9\" data-element_type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-bcc7881\" data-id=\"bcc7881\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-6f5ead1 elementor-widget elementor-widget-sc-heading\" data-id=\"6f5ead1\" data-element_type=\"widget\" data-widget_type=\"sc-heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div id=\"wt-at-6f5ead1\" class=\"headng-wrap center\">\r\n\t\t\t<div class=\"section-heading\">\r\n\t\t\t\t\t\t\t<h4\r\n\t\t\t\t \t\t\t\t>How am I supposed to act<\/h4>\r\n\t\t\t\t\t\t\t\t\t\t\t\t<h2\r\n\t\t\t\t \t\t\t\t>Emergency protocol GA Type 2<\/h2>\r\n\t\t\t\t\t\t\t\t\t\t\t\t<p\r\n\t\t\t\t \t\t\t\t>Know which is the emergency protocol for Argininosuccinic Acidemia type 2 (GA2)  <br>and learn how to act.&nbsp;<\/p>\r\n\t\t\t\t\t\t\t<\/div>\r\n\t\t<\/div>\r\n\r\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6e32c37 wt-align-center elementor-widget elementor-widget-sc_button\" data-id=\"6e32c37\" data-element_type=\"widget\" data-settings=\"{&quot;btn_style&quot;:&quot;1&quot;}\" data-widget_type=\"sc_button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div id=\"wt-at-6e32c37\" class=\"wt-button-wrap\">\r\n\t\t\t<a href=\"https:\/\/www.familiasga.com\/wp-content\/uploads\/2018\/11\/PROTOCOLO-GA2-2008-BIMDG.pdf\" class=\"dl-btn-2\">Get protocol<span><\/span><\/a>\t\t<\/div>\r\n\r\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-e81ee51 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"e81ee51\" data-element_type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-f38cc19\" data-id=\"f38cc19\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-28a4446 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"28a4446\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-699c5d6\" data-id=\"699c5d6\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-f7c10b6 elementor-invisible elementor-widget elementor-widget-sc-heading\" data-id=\"f7c10b6\" data-element_type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInUp&quot;}\" data-widget_type=\"sc-heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div id=\"wt-at-f7c10b6\" class=\"headng-wrap center\">\r\n\t\t\t<div class=\"section-heading\">\r\n\t\t\t\t\t\t\t<h4\r\n\t\t\t\t \t\t\t\t>Projects in progress!<\/h4>\r\n\t\t\t\t\t\t\t\t\t\t\t\t<h2\r\n\t\t\t\t \t\t\t\t>All help is Welcome<\/h2>\r\n\t\t\t\t\t\t\t\t\t\t\t\t<p\r\n\t\t\t\t \t\t\t\t>Every contribution, however small, makes a difference. <br>Your support can transform the lives of those with Glutaric Aciduria and other rare diseases.<\/p>\r\n\t\t\t\t\t\t\t<\/div>\r\n\t\t<\/div>\r\n\r\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-2f2a396 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"2f2a396\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-1189d79\" data-id=\"1189d79\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-ee334ba elementor-widget elementor-widget-dl-donations\" data-id=\"ee334ba\" data-element_type=\"widget\" data-settings=\"{&quot;dl_col_desktop&quot;:&quot;col-lg-4&quot;,&quot;dl_col_tablet&quot;:&quot;col-md-6&quot;,&quot;dl_col_mobile&quot;:&quot;col-sm-6&quot;}\" data-widget_type=\"dl-donations.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\r\n\t\t\r\n\t\t<div class=\"row donation-list\">\r\n\r\n\t\t\t\t\t\t\t\t<article class=\"donation-item col-lg-4 col-md-6 col-sm-6 post-1804 give_forms type-give_forms status-publish\" id=\"post-1804\">\r\n\t\t\t\t\t\t\t<div class=\"dl-donation-item\">\r\n\t\t\t\t\t<div class=\"donation-thumb\">\r\n\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/asipagac.com\/wp-content\/plugins\/give\/assets\/dist\/images\/give-placeholder.jpg\" alt=\"Placeholder\" \/>\t\t\t\t\t\t<a id=\"give-card-1804\" class=\"give-card donate-btn\" style=\"background-color: \" href=\"https:\/\/asipagac.com\/en\/donations\/compra-de-alimentacion-y-medicacion-especializada\/\">Donate Now<\/a>\t\t\t\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t<div class=\"donation-details\">\r\n\t\t\t\t\t\t\t\t\t\t\t<h3><a href=\"https:\/\/asipagac.com\/en\/donations\/compra-de-alimentacion-y-medicacion-especializada\/\">Purchase of Food and Specialized Medication<\/a><\/h3>\r\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<ul class=\"fund-info\">\r\n\t\t\t\t\t\t<li><i class=\"ti-bar-chart\"><\/i>Goal: &#36;100,000<\/li>\r\n\t\t\t\t\t\t<li><i class=\"ti-thumb-up\"><\/i>Raised: &#36;311<\/li>\r\n\t\t\t\t\t<\/ul>\r\n\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t<\/article>\r\n\t\t\t\t\t\t\t\t\t<article class=\"donation-item col-lg-4 col-md-6 col-sm-6 post-1805 give_forms type-give_forms status-publish\" id=\"post-1805\">\r\n\t\t\t\t\t\t\t<div class=\"dl-donation-item\">\r\n\t\t\t\t\t<div class=\"donation-thumb\">\r\n\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/asipagac.com\/wp-content\/plugins\/give\/assets\/dist\/images\/give-placeholder.jpg\" alt=\"Placeholder\" \/>\t\t\t\t\t\t<a id=\"give-card-1805\" class=\"give-card donate-btn\" style=\"background-color: \" href=\"https:\/\/asipagac.com\/en\/donations\/estudios-de-diagnostico-y-pruebas-de-tamiz-neonatal\/\">Donate Now<\/a>\t\t\t\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t<div class=\"donation-details\">\r\n\t\t\t\t\t\t\t\t\t\t\t<h3><a href=\"https:\/\/asipagac.com\/en\/donations\/estudios-de-diagnostico-y-pruebas-de-tamiz-neonatal\/\">Diagnosis and Neonatal screening<\/a><\/h3>\r\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<ul class=\"fund-info\">\r\n\t\t\t\t\t\t<li><i class=\"ti-bar-chart\"><\/i>Goal: &#36;100,000<\/li>\r\n\t\t\t\t\t\t<li><i class=\"ti-thumb-up\"><\/i>Raised: &#36;100<\/li>\r\n\t\t\t\t\t<\/ul>\r\n\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t<\/article>\r\n\t\t\t\t\t\t\t\t\t<article class=\"donation-item col-lg-4 col-md-6 col-sm-6 post-1806 give_forms type-give_forms status-publish\" id=\"post-1806\">\r\n\t\t\t\t\t\t\t<div class=\"dl-donation-item\">\r\n\t\t\t\t\t<div class=\"donation-thumb\">\r\n\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/asipagac.com\/wp-content\/plugins\/give\/assets\/dist\/images\/give-placeholder.jpg\" alt=\"Placeholder\" \/>\t\t\t\t\t\t<a id=\"give-card-1806\" class=\"give-card donate-btn\" style=\"background-color: \" href=\"https:\/\/asipagac.com\/en\/donations\/tratamientos-y-terapias\/\">Donate Now<\/a>\t\t\t\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t<div class=\"donation-details\">\r\n\t\t\t\t\t\t\t\t\t\t\t<h3><a href=\"https:\/\/asipagac.com\/en\/donations\/tratamientos-y-terapias\/\">Treatments and Therapies<\/a><\/h3>\r\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<ul class=\"fund-info\">\r\n\t\t\t\t\t\t<li><i class=\"ti-bar-chart\"><\/i>Goal: &#36;100,000<\/li>\r\n\t\t\t\t\t\t<li><i class=\"ti-thumb-up\"><\/i>Raised: &#36;200<\/li>\r\n\t\t\t\t\t<\/ul>\r\n\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t<\/article>\r\n\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Sobre la enfermedad La Aciduria Glut\u00e1rica es un trastorno metab\u00f3lico raro que afecta la manera en que el cuerpo procesa ciertas prote\u00ednas y grasas. Es una condici\u00f3n hereditaria, lo que significa que se transmite de padres a hijos a trav\u00e9s de los genes. Existen dos tipos principales deAciduria Glut\u00e1rica: Tipo I y Tipo II, cada<\/p>","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1448","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/asipagac.com\/en\/wp-json\/wp\/v2\/pages\/1448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/asipagac.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/asipagac.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/asipagac.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/asipagac.com\/en\/wp-json\/wp\/v2\/comments?post=1448"}],"version-history":[{"count":41,"href":"https:\/\/asipagac.com\/en\/wp-json\/wp\/v2\/pages\/1448\/revisions"}],"predecessor-version":[{"id":1894,"href":"https:\/\/asipagac.com\/en\/wp-json\/wp\/v2\/pages\/1448\/revisions\/1894"}],"wp:attachment":[{"href":"https:\/\/asipagac.com\/en\/wp-json\/wp\/v2\/media?parent=1448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}